{
  "data": [
    {
      "ingredient2": "Pentobarbital",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36419,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Pentoxifylline",
      "severity": "Moderate",
      "effect": "Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.",
      "management_text": "Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36420,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Perindopril",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36421,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Phenelzine",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36423,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Phenobarbital",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36424,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Phenoxybenzamine",
      "severity": "Moderate",
      "effect": "Avanafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Avanafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers.",
      "management_text": "Caution is advised if avanafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of avanafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating avanafil, and avanafil should be initiated at the lowest recommended dosage of 50 mg. In those patients already on an optimized dosage of avanafil, alpha blocker therapy should be initiated at the lowest dosage. The safety of avanafil in combination with alpha blockers may also be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36425,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Phentolamine",
      "severity": "Moderate",
      "effect": "Avanafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Avanafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers.",
      "management_text": "Caution is advised if avanafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of avanafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating avanafil, and avanafil should be initiated at the lowest recommended dosage of 50 mg. In those patients already on an optimized dosage of avanafil, alpha blocker therapy should be initiated at the lowest dosage. The safety of avanafil in combination with alpha blockers may also be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36426,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Phenylbutazone",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36427,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Phenytoin",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36428,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Pindolol",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36429,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Polythiazide",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36430,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Prazosin",
      "severity": "Moderate",
      "effect": "Avanafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Avanafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers.",
      "management_text": "Caution is advised if avanafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of avanafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating avanafil, and avanafil should be initiated at the lowest recommended dosage of 50 mg. In those patients already on an optimized dosage of avanafil, alpha blocker therapy should be initiated at the lowest dosage. The safety of avanafil in combination with alpha blockers may also be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36432,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Primidone",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36433,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Procarbazine",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36434,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Propranolol",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36435,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Quinapril",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36436,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Ramipril",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36437,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Rasagiline",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36438,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Reserpine",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36439,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Rifabutin",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36441,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Rifampicin",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36442,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Rifapentine",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36443,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Rufinamide",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36447,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Secobarbital",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36450,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Selegiline",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36451,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Silodosin",
      "severity": "Moderate",
      "effect": "Avanafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Avanafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers.",
      "management_text": "Caution is advised if avanafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of avanafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating avanafil, and avanafil should be initiated at the lowest recommended dosage of 50 mg. In those patients already on an optimized dosage of avanafil, alpha blocker therapy should be initiated at the lowest dosage. The safety of avanafil in combination with alpha blockers may also be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36453,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Somatotropin",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36458,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Sotalol",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36459,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Spironolactone",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36460,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "St. John's Wort",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36461,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Sulfinpyrazone",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36463,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Tamsulosin",
      "severity": "Moderate",
      "effect": "Avanafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Avanafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers.",
      "management_text": "Caution is advised if avanafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of avanafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating avanafil, and avanafil should be initiated at the lowest recommended dosage of 50 mg. In those patients already on an optimized dosage of avanafil, alpha blocker therapy should be initiated at the lowest dosage. The safety of avanafil in combination with alpha blockers may also be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36464,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Telmisartan",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36468,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Terazosin",
      "severity": "Moderate",
      "effect": "Avanafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Avanafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers.",
      "management_text": "Caution is advised if avanafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of avanafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating avanafil, and avanafil should be initiated at the lowest recommended dosage of 50 mg. In those patients already on an optimized dosage of avanafil, alpha blocker therapy should be initiated at the lowest dosage. The safety of avanafil in combination with alpha blockers may also be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36470,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Timolol",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36471,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Tolazoline",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36472,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Torasemide",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36473,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Trandolapril",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36474,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Tranylcypromine",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36475,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Treprostinil",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36476,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Triamterene",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36477,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Trichlormethiazide",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36478,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Trimethaphan",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36479,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Troglitazone",
      "severity": "Moderate",
      "effect": "Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.",
      "management_text": "The use of avanafil in combination with CYP450 3A4 inducers is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36480,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Valsartan",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36483,
      "ingredient1": "Avanafil"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Major",
      "effect": "Quinolones such as ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.",
      "management_text": "Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, as well as bepridil.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 21616,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Amisulpride",
      "severity": "Major",
      "effect": "Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution and close clinical monitoring (e.g., electrocardiogram, serum electrolytes) are recommended if amisulpride is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 22065,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Major",
      "effect": "The use of bupropion is associated with a dose-related risk of seizures. The risk may be further increased when coadministered with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline).",
      "management_text": "Extreme caution is advised if bupropion is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with a history of seizures or other risk factors for seizures (e.g., head trauma; brain tumor; severe hepatic cirrhosis; metabolic disorders; CNS infections; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; diabetes treated with oral hypoglycemic agents or insulin). Bupropion as well as concomitant medications should be initiated at the lower end of the dosage range and titrated gradually as needed and as tolerated. The maximum recommended dosage for the specific bupropion formulation should not be exceeded. Bupropion should be discontinued and not restarted in patients who experience a seizure during treatment.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 28358,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Arsenic trioxide",
      "severity": "Major",
      "effect": "Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "If possible, medications that are known to prolong the QT interval should be discontinued prior to initiating therapy with arsenic trioxide and withheld for at least several weeks after completion of therapy. Caution is advised if concomitant use cannot be avoided. Patients should have frequent ECGs and be monitored for arrhythmias when QT interval is prolonged. An absolute QT interval exceeding 500 msec will require immediate action to correct concomitant risk factors, if any, as well as a thorough assessment of the need for continued therapy. Patients who develop syncope or arrhythmia should be hospitalized for clinical and laboratory monitoring.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 31652,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Lumefantrine",
      "severity": "Major",
      "effect": "Artemether-lumefantrine may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided. Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days). Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 31934,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Major",
      "effect": "Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.",
      "management_text": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 39273,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Bempedoic acid",
      "severity": "Major",
      "effect": "Concomitant administration of bempedoic acid may potentiate the risk of tendon rupture or injury associated with fluoroquinolones and corticosteroids. The mechanism is unknown. Tendon rupture or injury have most frequently involved the rotator cuff (the shoulder), biceps tendon, or Achilles tendon. Tendon rupture may occur within weeks to months of starting treatment with bempedoic acid.",
      "management_text": "Caution is recommended if bempedoic acid is prescribed in combination with corticosteroids or fluoroquinolones, particularly in patients with other concomitant risk factors (e.g., age over 60 years, renal failure, previous tendon disorders). Treatment with bempedoic acid should be stopped immediately if rupture of a tendon occurs. Discontinuation of treatment with bempedoic acid should be considered if the patient experiences joint pain, swelling, or inflammation. At the first sign of tendinitis or tendon rupture, the patient should be instructed to rest, avoid exercise, avoid using the affected area, and to contact their healthcare provider. An alternative therapy should be considered in patients with a history of tendon disorders or tendon rupture.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 40467,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Cabozantinib",
      "severity": "Major",
      "effect": "Cabozantinib can cause prolongation of the QT interval.",
      "management_text": "Caution and close clinical monitoring are recommended if cabozantinib is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 53162,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ceritinib",
      "severity": "Major",
      "effect": "Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting ceritinib therapy and periodically during treatment.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 61257,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)",
      "severity": "Major",
      "effect": "INTERVAL: The use of live, attenuated cholera vaccine with systemic antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Vibrio cholerae, thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.",
      "management_text": "Live, attenuated cholera vaccine should not be administered during or for at least 14 days after treatment with systemic antibiotics.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 64597,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Crizotinib",
      "severity": "Major",
      "effect": "Crizotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if crizotinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting crizotinib therapy and periodically during treatment.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 75889,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Deflazacort",
      "severity": "Major",
      "effect": "Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.",
      "management_text": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 82217,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Dronedarone",
      "severity": "Major",
      "effect": "Dronedarone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of dronedarone with other drugs that can prolong the QT interval is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 92580,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Insulin aspart (aspart)",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 115587,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Insulin degludec",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 115802,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Insulin detemir",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 116090,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Insulin glulisine",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 116576,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Saquinavir",
      "severity": "Major",
      "effect": "Saquinavir in combination with ritonavir may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of ritonavir-boosted saquinavir with other drugs that can prolong the QT interval is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 118425,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Iopamidol",
      "severity": "Major",
      "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.",
      "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 120681,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ivabradine",
      "severity": "Major",
      "effect": "Due to its bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased when ivabradine is used with drugs that prolong the QT interval.",
      "management_text": "Coadministration of ivabradine with drugs that can prolong the QT interval should generally be avoided. Caution and cardiac monitoring are recommended if concomitant use is required.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 121318,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Macimorelin",
      "severity": "Major",
      "effect": "Macimorelin can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of macimorelin with other drugs that can prolong the QT interval should generally be avoided. A sufficient washout period following discontinuation of these drugs is recommended prior to macimorelin administration. Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 134421,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Iohexol",
      "severity": "Major",
      "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.",
      "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 147828,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Osimertinib",
      "severity": "Major",
      "effect": "Osimertinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if osimertinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting osimertinib therapy and periodically during treatment.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 148601,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ozanimod",
      "severity": "Major",
      "effect": "Due to the risk of bradycardia and atrioventricular (AV) block, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of ozanimod treatment in patients receiving drugs that prolong the QT interval.",
      "management_text": "Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 149910,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Panobinostat",
      "severity": "Major",
      "effect": "Panobinostat can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Concomitant use of panobinostat with other drugs that can prolong the QT interval should generally be avoided. Anti-emetic drugs with known QT prolonging risk such as dolasetron, granisetron, ondansetron, palonosetron, and tropisetron may be used with frequent ECG monitoring. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting panobinostat therapy and periodically during treatment as clinically indicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 150500,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Pasireotide",
      "severity": "Major",
      "effect": "Pasireotide can cause bradycardia and QT prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if pasireotide is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting pasireotide therapy and periodically during treatment in accordance with the product labeling. Hypokalemia and hypomagnesemia must be corrected prior to pasireotide administration.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 151072,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Pimozide",
      "severity": "Major",
      "effect": "Pimozide can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with pimozide. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.",
      "management_text": "Coadministration of pimozide with other drugs that can prolong the QT interval is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 154361,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Procainamide",
      "severity": "Major",
      "effect": "Quinolones such as ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.",
      "management_text": "Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, as well as bepridil.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 157203,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ribociclib",
      "severity": "Major",
      "effect": "Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of ribociclib with other drugs that can prolong the QT interval should generally be avoided. However, if concomitant use is required, caution and clinical and laboratory monitoring are recommended. ECGs should be assessed prior to initiation of treatment, during treatment when clinically necessary, and more frequently if QTcF prolongation occurs at any time during treatment. Ribociclib should be permanently discontinued if the QTcF interval prolongation is either greater than 500 msec or there is a greater than 60 msec change from baseline and associated with any of the following: Torsades de Pointes, polymorphic ventricular tachycardia, unexplained syncope, or signs/symptoms of serious arrhythmia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 161231,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Selpercatinib",
      "severity": "Major",
      "effect": "Selpercatinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if selpercatinib is used in combination with other drugs that can prolong the QT interval. An electrocardiogram and serum electrolyte levels should be obtained prior to initiating selpercatinib therapy and periodically during treatment as appropriate based on individual risk factors including diarrhea. Correct hypokalemia, hypomagnesemia, and/or hypocalcemia before starting treatment and during treatment, as they may be risk factors for ventricular arrhythmias.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 165226,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Siponimod",
      "severity": "Major",
      "effect": "Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of siponimod treatment in patients receiving drugs that prolong the QT interval.",
      "management_text": "Siponimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with siponimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 166297,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Vandetanib",
      "severity": "Major",
      "effect": "Vandetanib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided. Should treatment with other QT-prolonging drugs be required, the manufacturer recommends more frequent monitoring of the ECG as well as serum potassium, magnesium, and calcium levels.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 175249,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Vemurafenib",
      "severity": "Major",
      "effect": "Vemurafenib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of vemurafenib with other drugs that can prolong the QT interval is not recommended. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting vemurafenib therapy and after dose modification.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 175531,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Escitalopram",
      "severity": "Major",
      "effect": "Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. When escitalopram is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 179296,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Fingolimod",
      "severity": "Major",
      "effect": "Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of fingolimod treatment in patients receiving drugs that prolong the QT interval. Fingolimod can cause a decrease in heart rate during initiation of therapy that is apparent within an hour of the first dose and maximal at approximately 6 hours postdose in most cases, but occasionally up to 20 hours after the first dose.",
      "management_text": "Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, close monitoring is recommended during initiation of fingolimod treatment in patients receiving concomitant drugs that can prolong the QT interval, patients with significant QT prolongation (QTc >470 msec in females or >450 msec in males), or patients with relevant risk factors for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital QT prolongation).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 182468,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Glipizide",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 185835,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Glyburide",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 185963,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Major",
      "effect": "Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Because COVID-19 may disproportionately affect the elderly and individuals with preexisting heart disease, and cardiac complications such as myocarditis and cardiomyopathy as well as organ failure may occur in patients with severe COVID-19, it appears likely that hospitalized patients with COVID-19 may represent a particularly susceptible and high-risk population, and other, less critically ill patients may not have the same arrhythmic risk.",
      "management_text": "Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.g., QTc >=500 msec) or congenital long QT syndrome. Close monitoring of QTc interval, electrolyte levels, and renal and hepatic function is recommended if concomitant use is required and benefits are anticipated to outweigh the risks. Electrolyte abnormalities should be corrected prior to initiating treatment with chloroquine or hydroxychloroquine. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Because chloroquine and hydroxychloroquine are eliminated slowly from the body, the potential for drug interactions should be observed for a prolonged period following their discontinuation.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 187053,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Major",
      "effect": "Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged. Persistent QTc measurements exceeding 500 msec will require suspension of iloperidone therapy and immediate action to correct any concomitant risk factors before resuming treatment.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 187829,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Bedaquiline",
      "severity": "Major",
      "effect": "Bedaquiline can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting bedaquiline therapy and periodically during treatment in accordance with the product labeling. Hypokalemia, hypomagnesemia, and hypocalcemia must be corrected prior to bedaquiline administration.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 189351,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Papaverine",
      "severity": "Major",
      "effect": "Intracoronary administration of papaverine has been associated with QT interval prolongation and torsade de pointes (TdP) arrhythmia. The risk may theoretically increase in patients receiving concomitant medications that can also prolong the QT interval or cause bradycardia. The precise mechanism of papaverine-induced ventricular tachyarrhythmias has not been delineated, but may involve inhibition of potassium currents and prolongation of the action potential duration.",
      "management_text": "Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 193029,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Tolbutamide",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 193937,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Typhoid vaccine (live)",
      "severity": "Major",
      "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.",
      "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 194221,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Tramadol",
      "severity": "Major",
      "effect": "The risk of seizures may be increased during coadministration of tramadol with any substance that can reduce the seizure threshold, such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. These agents are often individually epileptogenic and may have additive effects when combined. Many of these agents also exhibit CNS- and/or respiratory-depressant effects, which may be enhanced during their concomitant use with tramadol.",
      "management_text": "Caution is advised if tramadol is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5944,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Major",
      "effect": "Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.",
      "management_text": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 11292,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Anagrelide",
      "severity": "Major",
      "effect": "Anagrelide can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of anagrelide with other drugs that can prolong the QT interval should generally be avoided. Patients receiving anagrelide should have a cardiovascular examination, including an ECG, prior to initiation of treatment and monitored for cardiovascular effects during treatment. Hypokalemia or hypomagnesemia must be corrected prior to therapy and electrolytes monitored periodically during therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 24824,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Triamcinolone",
      "severity": "Major",
      "effect": "Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.",
      "management_text": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 30999,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Betamethasone",
      "severity": "Major",
      "effect": "Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.",
      "management_text": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 41958,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Chloroquine",
      "severity": "Major",
      "effect": "Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Because COVID-19 may disproportionately affect the elderly and individuals with preexisting heart disease, and cardiac complications such as myocarditis and cardiomyopathy as well as organ failure may occur in patients with severe COVID-19, it appears likely that hospitalized patients with COVID-19 may represent a particularly susceptible and high-risk population, and other, less critically ill patients may not have the same arrhythmic risk.",
      "management_text": "Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.g., QTc >=500 msec) or congenital long QT syndrome. Close monitoring of QTc interval, electrolyte levels, and renal and hepatic function is recommended if concomitant use is required and benefits are anticipated to outweigh the risks. Electrolyte abnormalities should be corrected prior to initiating treatment with chloroquine or hydroxychloroquine. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Because chloroquine and hydroxychloroquine are eliminated slowly from the body, the potential for drug interactions should be observed for a prolonged period following their discontinuation.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 63100,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Chlorpropamide",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 63771,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Major",
      "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 66998,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Major",
      "effect": "Clozapine has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can cause QT prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clozapine treatment alone has been associated with ventricular arrhythmia, torsade de pointes, cardiac arrest, and sudden death.",
      "management_text": "Caution is recommended if clozapine is used in combination with other drugs that can prolong the QT interval. Serum electrolytes, including potassium, magnesium and calcium, should be measured at baseline and periodically during treatment, and any abnormalities corrected prior to initiating clozapine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 72382,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Quinidine",
      "severity": "Major",
      "effect": "Quinolones such as ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.",
      "management_text": "Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, as well as bepridil.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 85220,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Methadone",
      "severity": "Major",
      "effect": "Methadone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. High dosages of methadone alone have been associated with QT interval prolongation and torsade de pointes.",
      "management_text": "Caution is recommended if methadone is used in combination with other drugs that can prolong the QT interval, particularly in the setting of chronic pain management or methadone maintenance for opioid dependency where high dosages may be employed. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If taking drugs that also cause CNS-depressant or orthostatic effects (e.g., sedating antihistamines, psychotropic drugs like tricyclic antidepressants, phenothiazines, and neuroleptics), patients should be made aware of the possibility of additive effects with methadone and counseled to avoid activities requiring mental alertness until they know how these agents affect them.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 88335,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Disopyramide",
      "severity": "Major",
      "effect": "Quinolones such as ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.",
      "management_text": "Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, as well as bepridil.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 88781,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Dofetilide",
      "severity": "Major",
      "effect": "Like other class III antiarrhythmic agents, dofetilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of dofetilide with other drugs that can prolong the QT interval has not been studied and is not recommended.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 89747,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Dolasetron",
      "severity": "Major",
      "effect": "Dolasetron can cause dose-related prolongation of the QT interval via its pharmacologically active metabolite, hydrodolasetron. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if dolasetron is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval. ECG monitoring may be appropriate in high-risk patients. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 89995,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Droperidol",
      "severity": "Major",
      "effect": "The use of droperidol has been associated with QT interval prolongation, torsade de pointes and other serious arrhythmias, and sudden death. The concurrent administration of agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins), drugs known to increase the QT interval (e.g., phenothiazines, tricyclic antidepressants, antiarrhythmic agents, etc.), certain other drugs (benzodiazepines, volatile anesthetics, intravenous opiates), or alcohol abuse may increase the risk of prolonged QT syndrome.",
      "management_text": "The manufacturer recommends extreme caution if droperidol must be given concomitantly with these agents. The dosage of droperidol should be individualized and titrated to the desired effect. Routine vital sign and ECG monitoring is recommended. When droperidol is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 92959,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Efavirenz",
      "severity": "Major",
      "effect": "Efavirenz can cause significant QT interval prolongation in patients with the CYP450 2B6 *6/*6 genotype due to reduced metabolic clearance of the drug stemming from decreased levels of functional CYP450 2B6 isoenzyme.",
      "management_text": "Alternatives to efavirenz should be considered in patients receiving other drugs that can prolong the QT interval. Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 96027,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Glimepiride",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 108096,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Repaglinide",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 109761,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Insulin glargine",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 116305,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Insulin human (isophane)",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 116793,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Warfarin",
      "severity": "Major",
      "effect": "Some quinolone antibiotics have been reported to potentiate the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants. The exact mechanism is unknown but may involve inhibition of coumarin metabolism and/or depletion of certain clotting factors due to suppression of vitamin K-producing intestinal flora.",
      "management_text": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if a quinolone antibiotic is prescribed during coumarin anticoagulant therapy. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of quinolone therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 122472,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Methylprednisolone",
      "severity": "Major",
      "effect": "Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.",
      "management_text": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 135784,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Mifepristone",
      "severity": "Major",
      "effect": "Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, coadministration with other drugs that can prolong the QT interval should generally be avoided. Caution is recommended if no alternatives exist and concomitant use is required. Serum potassium should be assessed prior to starting mifepristone and 1 to 2 weeks following initiation of therapy or an increase in dosage, and periodically as needed. Hypokalemia must be corrected prior to initiation of mifepristone. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heart rhythm.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 140764,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Nateglinide",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 141881,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Prednisone",
      "severity": "Major",
      "effect": "Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.",
      "management_text": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 156778,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sotalol",
      "severity": "Major",
      "effect": "Quinolones such as ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.",
      "management_text": "Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, as well as bepridil.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 167096,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Tolazamide",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 172582,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Toremifene",
      "severity": "Major",
      "effect": "Toremifene has the potential to prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of toremifene with other drugs that can prolong the QT interval should generally be avoided. If treatment with other QT-prolonging drugs is required, interruption of toremifene therapy should be considered. Caution and clinical monitoring are recommended if concomitant use is unavoidable. In patients at increased risk, electrocardiograms (ECGs) are recommended at baseline and as clinically indicated. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 172958,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ziprasidone",
      "severity": "Major",
      "effect": "Ziprasidone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.",
      "management_text": "Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 177254,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Prednisolone",
      "severity": "Major",
      "effect": "Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.",
      "management_text": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 182864,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Fludrocortisone",
      "severity": "Major",
      "effect": "Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.",
      "management_text": "Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 183253,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Major",
      "effect": "Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Haloperidol treatment alone has been associated with a number of reported cases of torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with haloperidol. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.",
      "management_text": "Caution is recommended if haloperidol is used in combination with other drugs that can prolong the QT interval, particularly when administered intravenously or at higher than recommended dosages.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 186572,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Insulin lispro",
      "severity": "Major",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or insulin. Although hyperglycemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 186779,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ibutilide",
      "severity": "Major",
      "effect": "Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 187437,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Mesoridazine",
      "severity": "Major",
      "effect": "Mesoridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Mesoridazine overdosage has been associated with ventricular arrhythmias and death. The extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s). In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with mesoridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.",
      "management_text": "Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 193590,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Thioridazine",
      "severity": "Major",
      "effect": "Thioridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with thioridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.",
      "management_text": "Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 193856,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Aminolevulinic acid",
      "severity": "Major",
      "effect": "Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.",
      "management_text": "Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid.  Some authorities recommend avoiding exposure to any photosensitizing agent for up to 2 weeks after oral administration of aminolevulinic acid, if possible.  Patients should also avoid exposure of the eyes and skin to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 48 hours after receiving aminolevulinic acid.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 249979,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Halofantrine",
      "severity": "Major",
      "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses.  QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.  The manufacturer recommends performing an ECG before initiating halofantrine therapy and monitoring cardiac rhythm during and for 8 to 12 hours after completion of therapy.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 280162,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Cisapride",
      "severity": "Major",
      "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 285053,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Abiraterone",
      "severity": "Moderate",
      "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).",
      "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 1468,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Formoterol",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 7373,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10320,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Albiglutide",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11903,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Salbutamol",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12197,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Alogliptin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17864,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Pioglitazone",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18342,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Amifampridine",
      "severity": "Moderate",
      "effect": "The use of amifampridine is associated with a dose-related risk of seizures, and the risk may be further increased when coadministered with other drugs that can reduce the seizure threshold such as antidepressants, antimalarials, neuroleptics, phenothiazines, and quinolones.",
      "management_text": "Caution is advised if amifampridine is coadministered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with other risk factors for seizures (e.g., head trauma; brain tumor; severe hepatic cirrhosis; metabolic disorders; CNS infections; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; diabetes treated with oral hypoglycemic agents or insulin).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20575,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sodium citrate",
      "severity": "Moderate",
      "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.",
      "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26234,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Arformoterol",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 30044,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Aripiprazole",
      "severity": "Moderate",
      "effect": "It is uncertain whether aripiprazole causes clinically significant prolongation of the QT interval.",
      "management_text": "Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation. ECG monitoring may be advisable in some cases, such as in patients with a history of cardiac arrhythmias or congenital or family history of long QT syndrome. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 30496,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Asenapine",
      "severity": "Moderate",
      "effect": "Asenapine may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of asenapine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 32865,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Balsalazide",
      "severity": "Moderate",
      "effect": "Balsalazide may be rendered less effective when administered with certain antibiotics. Balsalazide is acted upon in the lower gut by bacterial azoreduction to produce mesalamine, the therapeutically active ingredient. Although no studies have been done, it is theorized that oral antibiotics can interfere with this reduction to mesalamine.",
      "management_text": "If the patient must receive oral antibiotics, consideration should be given to using another 5-aminosalicylate such as mesalamine.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 38603,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Bicalutamide",
      "severity": "Moderate",
      "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).",
      "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 43545,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Bisacodyl",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 44577,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Calcium Phosphate",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 45667,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Bosutinib",
      "severity": "Moderate",
      "effect": "Bosutinib may cause QTc prolongation without associated arrhythmia. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if bosutinib is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 46648,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Canagliflozin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 54333,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Choline salicylate",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64922,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Cilostazol",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 65327,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Potassium citrate",
      "severity": "Moderate",
      "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.",
      "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 67345,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 67900,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Citric acid",
      "severity": "Moderate",
      "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.",
      "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 68682,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Polyethylene glycol (3350 with electrolytes)",
      "severity": "Moderate",
      "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).",
      "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 69091,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Clomipramine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 70706,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Dapagliflozin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78828,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Saxagliptin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 79075,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Dasatinib",
      "severity": "Moderate",
      "effect": "In vitro data suggest that dasatinib has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if dasatinib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 80243,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Oxaprozin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81198,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Degarelix",
      "severity": "Moderate",
      "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).",
      "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 82442,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Desipramine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 83523,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Deutetrabenazine",
      "severity": "Moderate",
      "effect": "Deutetrabenazine has been associated with modest QT interval prolongation. In addition, central nervous system (CNS)-depressant effects may be additively or synergistically increased in patients taking deutetrabenazine with certain other drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "Coadministration of deutetrabenazine with other drugs that can prolong the QT interval should generally be avoided. Deutetrabenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. If concomitant use is required, assessment of baseline QT interval and periodic monitoring during therapy may be considered. In addition, dosage reduction may be considered in patients on concurrent therapy with a strong CYP450 2D6 inhibitor, or in patients who are poor metabolizers of CYP450 2D6.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 84401,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Doxepin",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 91186,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Dulaglutide",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 93494,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Empagliflozin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98057,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Rilpivirine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98448,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Encorafenib",
      "severity": "Moderate",
      "effect": "Encorafenib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of encorafenib with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Hypokalemia and hypomagnesemia should be corrected prior to initiation of encorafenib treatment, and electrolytes periodically monitored during treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Withhold, reduce dose, or permanently discontinue encorafenib in accordance with the product labeling for QTc exceeding 500 msec.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98962,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Lopinavir",
      "severity": "Moderate",
      "effect": "Lopinavir in combination with ritonavir may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of lopinavir-ritonavir with other drugs that can prolong the QT interval should generally be avoided. Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 100929,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Pirbuterol",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 101858,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Phenyl salicylate",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 102521,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Selenium",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 102915,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Mestranol",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. The non-hormonal placebo pills included in some oral contraceptive preparations may contain iron, usually ferrous fumarate. Concomitant administration of these iron pills may significantly decrease the gastrointestinal absorption of antibiotics such as quinolones and tetracyclines. The mechanism is chelation of the antibiotic by the iron cation, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. In general, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after iron preparations to minimize the potential for interaction. The administration of tetracycline antibiotics and iron preparations should be separated by at least three to four hours, although this may not prevent the interaction with doxycycline. Concomitant use of doxycycline and iron preparations should be avoided if possible.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 104388,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Promethazine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 108604,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Semaglutide",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 110862,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Olodaterol",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 113819,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Zinc sulfate",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 113944,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Triptorelin",
      "severity": "Moderate",
      "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).",
      "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 114299,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Vilanterol",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 114703,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Inotuzumab ozogamicin",
      "severity": "Moderate",
      "effect": "Inotuzumab ozogamicin may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of inotuzumab ozogamicin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use cannot be avoided or if inotuzumab ozogamicin is used in patients with other risk factors for QT prolongation. The manufacturer suggests obtaining electrocardiograms and serum electrolytes at baseline and regularly during treatment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 115363,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Paliperidone",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 118060,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Isoprenaline",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 120161,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Mycophenolic acid",
      "severity": "Moderate",
      "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.",
      "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 125058,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Lithium carbonate",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 131776,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Lofexidine",
      "severity": "Moderate",
      "effect": "Lofexidine has been associated with asymptomatic prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Coadministration of lofexidine with other agents with hypotensive effects may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution is recommended if lofexidine is used in combination with other drugs that can prolong the QT interval. Periodic monitoring with on-treatment electrocardiograms and serum electrolytes (magnesium, potassium) should be considered. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 132208,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Magnesium chloride",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 134632,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Methyl aminolevulinate (topical)",
      "severity": "Moderate",
      "effect": "Concomitant use of aminolevulinate topical preparations with other known photosensitizing agents may enhance the phototoxic reaction to photodynamic therapy. Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John's Wort).",
      "management_text": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid exposure of treated areas to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) during the period between application of aminolevulinic acid or methyl aminolevulinate and photoactivation, and for 48 hours post-illumination. Concomitant use with other topical medicinal products should be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 138634,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Midostaurin",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 140477,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Oliceridine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 147068,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Osilodrostat",
      "severity": "Moderate",
      "effect": "Osilodrostat can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if osilodrostat is used in combination with other drugs that can prolong the QT interval. An electrocardiogram and serum electrolyte levels should be obtained prior to initiating osilodrostat therapy and periodically thereafter. Correct hypokalemia and/or hypomagnesemia before starting treatment and as indicated during treatment, as they may be risk factors for ventricular arrhythmias.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 148380,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Pazopanib",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 151259,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Pimavanserin",
      "severity": "Moderate",
      "effect": "Pimavanserin may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of pimavanserin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 154118,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Pitolisant",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 155066,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Posaconazole",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 155918,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Pramlintide",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 156341,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Propafenone",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 157797,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Quetiapine",
      "severity": "Moderate",
      "effect": "There is some concern that quetiapine may have additive cardiovascular effects in combination with other drugs that are known to prolong the QT interval of the electrocardiogram.",
      "management_text": "Coadministration of quetiapine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. In addition, if combination therapy with agents with anticholinergic properties is required, caution is advised, particularly in the elderly and those with underlying organic brain disease.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158802,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Rivastigmine",
      "severity": "Moderate",
      "effect": "Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.",
      "management_text": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 162239,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Romidepsin",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 162648,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Rucaparib",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 163206,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Salsalate",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 164128,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sertraline",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 165525,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sevoflurane",
      "severity": "Moderate",
      "effect": "Sevoflurane may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if sevoflurane is used in combination with other drugs that can prolong the QT interval. The patient's cardiovascular status and serum electrolytes should be closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 165704,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sitagliptin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166523,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Solifenacin",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166662,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sunitinib",
      "severity": "Moderate",
      "effect": "Sunitinib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if sunitinib is used in combination with other drugs that can prolong the QT interval. Periodic monitoring with on-treatment electrocardiograms and serum electrolytes (magnesium, potassium) should be considered. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 167893,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Telavancin",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 169168,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Tetrabenazine",
      "severity": "Moderate",
      "effect": "Tetrabenazine may cause modest prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of tetrabenazine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 170532,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Thalidomide",
      "severity": "Moderate",
      "effect": "Thalidomide can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Peripheral neuropathy is a common, potentially severe side effect of thalidomide that may be irreversible. Thalidomide can cause bradycardia and may potentiate the risk of torsade de pointes arrhythmia associated with the use of drugs that prolong the QT interval.",
      "management_text": "Caution is advised if thalidomide is used in combination with other neurotoxic agents. All patients treated with thalidomide should be examined at monthly intervals for the first three months of therapy and periodically thereafter to detect early signs of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Electrophysiological testing may be performed at baseline and every six months during therapy to detect asymptomatic neuropathy. Consideration should be given to immediate discontinuation of thalidomide in patients who develop peripheral neuropathy to limit further damage. Symptoms may improve or return to baseline in some patients upon discontinuation of thalidomide, although the complete time course of this toxicity has not been fully characterized. Because bradycardia is a risk factor for torsade de pointes arrhythmia, caution is advised when thalidomide is used with drugs that can prolong the QT interval or induce torsade de pointes arrhythmia. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat. A dose reduction of thalidomide or discontinuation may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 170763,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Triclabendazole",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 174092,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Valbenazine",
      "severity": "Moderate",
      "effect": "Valbenazine may cause modest prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Central nervous system (CNS)-depressant effects may be additively or synergistically increased in patients taking valbenazine with certain other drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "Caution and clinical monitoring are recommended if concomitant use of valbenazine with other drugs that can prolong the QT interval is required. Valbenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. In patients with other risk factors for QT prolongation, the QT interval should be assessed before increasing the dose of valbenazine. The manufacturer recommends that valbenazine dosage be reduced to 40 mg once daily in patients on concomitant therapy with a strong CYP450 3A4 inhibitor (e.g., itraconazole, ketoconazole, clarithromycin). Valbenazine dose reduction should also be considered in patients on concurrent therapy with a strong CYP450 2D6 inhibitor (e.g., paroxetine, fluoxetine, quinidine), or in patients who are poor metabolizers of CYP450 2D6.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 175060,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Entrectinib",
      "severity": "Moderate",
      "effect": "Entrectinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of entrectinib with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have electrocardiograms (ECGs) performed prior to initiation of entrectinib and periodically during treatment as appropriate based on individual risk factors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178005,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Enzalutamide",
      "severity": "Moderate",
      "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).",
      "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178153,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Eribulin",
      "severity": "Moderate",
      "effect": "Eribulin may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if eribulin is used in combination with other drugs that can prolong the QT interval. Baseline and periodic monitoring of electrocardiograms and serum electrolytes (potassium, magnesium) should be considered, and hypokalemia or hypomagnesemia corrected prior to initiating treatment with eribulin. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 178961,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ertugliflozin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 179124,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Exenatide",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181407,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ezogabine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 181519,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Tetraferric tricitrate decahydrate",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 182193,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Flecainide",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 182644,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Fostemsavir",
      "severity": "Moderate",
      "effect": "Fostemsavir can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if fostemsavir is used in combination with other drugs that can prolong the QT interval. Consider obtaining electrocardiogram and serum electrolyte levels prior to initiating fostemsavir therapy and periodically thereafter, particularly in patients with risk factors for torsade de pointes and/or receiving one or more potent CYP450 3A4 inhibitors (e.g., azole antifungal agents; cobicistat; protease inhibitors; ketolide and certain macrolide antibiotics; ceritinib; idelalisib; nefazodone) or P-gp inhibitors (e.g., cyclosporine; diltiazem; quinidine; quinine; tacrolimus; verapamil). Correct hypokalemia and/or hypomagnesemia before starting treatment and as indicated during treatment, as they may be risk factors for ventricular arrhythmias.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 184650,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Gilteritinib",
      "severity": "Moderate",
      "effect": "Gilteritinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution and clinical monitoring are recommended if gilteritinib is used in combination with other drugs that can prolong the QT interval. Patients should have electrocardiograms (ECGs) performed prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185490,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Glasdegib",
      "severity": "Moderate",
      "effect": "Glasdegib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of glasdegib with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have electrocardiograms (ECGs) performed prior to initiation of treatment with glasdegib, approximately one week after initiation, and then once monthly for the next two months, although patients with risk factors may require more frequent and ongoing ECG monitoring.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185615,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Histrelin",
      "severity": "Moderate",
      "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).",
      "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 186715,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Indacaterol",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188248,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Glycerin",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188885,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Calcium carbonate",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 189775,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Calcium glubionate anhydrous",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 189823,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Frangula purshiana bark",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 189901,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Castor oil",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 189934,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Iron",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190762,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ferrous fumarate",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190785,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ferrous sulfate anhydrous",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190823,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Aluminum hydroxide",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190856,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ginkgo biloba",
      "severity": "Moderate",
      "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures. There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Ginkgo products may contain varying amounts of 4'-O-methylpyridoxine (ginkgotoxin), a known neurotoxin found primarily in ginkgo biloba seeds but also detected in lesser amounts in the leaves. In vivo, 4'-O-methylpyridoxine competes with vitamin B6, which causes an indirect inhibition of glutamate decarboxylase and subsequent decrease in the formation of gamma-aminobutyric acid (GABA) in the brain. There have been published case reports of generalized convulsions and vomiting within several hours after ingestion of large amounts of ginkgo nuts/seeds, including in young children and healthy individuals with no known personal or family history of epilepsy.",
      "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation. Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 191386,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Halothane",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 191512,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Indium In-111 oxyquinoline",
      "severity": "Moderate",
      "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.",
      "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 191802,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Magnesium carbonate",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192304,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Magnesium hydroxide",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192386,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Magnesium oxide",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192416,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Mineral oil",
      "severity": "Moderate",
      "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.",
      "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192712,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Primaquine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193244,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Terfenadine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 247435,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Valdecoxib",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 258078,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sodium bicarbonate",
      "severity": "Moderate",
      "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.",
      "management_text": "Concomitant use should generally be avoided.  Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 259965,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Tacrine",
      "severity": "Moderate",
      "effect": "Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%).",
      "management_text": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.  Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 268533,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Pralsetinib",
      "severity": "Moderate",
      "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 279169,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Probucol",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution and clinical monitoring are recommended if multiple agents associated with QT interval prolongation are prescribed together.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 285018,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Relugolix",
      "severity": "Moderate",
      "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 285246,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ritodrine",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 285464,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Rofecoxib",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 287665,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sodium phosphate, monobasic",
      "severity": "Moderate",
      "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.",
      "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 294729,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Picosulfuric acid",
      "severity": "Moderate",
      "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.",
      "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 296648,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Acarbose",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 3173,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Famotidine",
      "severity": "Moderate",
      "effect": "Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution and clinical monitoring are recommended if famotidine is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 6654,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Adenosine",
      "severity": "Moderate",
      "effect": "Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents that can prolong the QT interval may increase that risk as well.",
      "management_text": "Adenosine should be used with caution in patients receiving drugs that may prolong the QT interval. Adenosine should be discontinued immediately if severe bradycardia occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 9534,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ethinylestradiol",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. The non-hormonal placebo pills included in some oral contraceptive preparations may contain iron, usually ferrous fumarate. Concomitant administration of these iron pills may significantly decrease the gastrointestinal absorption of antibiotics such as quinolones and tetracyclines. The mechanism is chelation of the antibiotic by the iron cation, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. In general, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after iron preparations to minimize the potential for interaction. The administration of tetracycline antibiotics and iron preparations should be separated by at least three to four hours, although this may not prevent the interaction with doxycycline. Concomitant use of doxycycline and iron preparations should be avoided if possible.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10868,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Alfuzosin",
      "severity": "Moderate",
      "effect": "Alfuzosin may cause modest prolongation of the QTc interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if alfuzosin is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If taking drugs that also cause CNS or orthostatic effects (e.g., psychotropic drugs like tricyclic antidepressants, phenothiazines, and neuroleptics), patients should be made aware of the possibility of additive effects with alfuzosin and counseled to avoid activities requiring mental alertness until they know how these agents affect them.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 16264,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Metformin",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18108,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Amitriptyline",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22515,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 23551,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Propofol",
      "severity": "Moderate",
      "effect": "Treatment with propofol may lead to prolongation of the QT interval; however, the extent of prolongation and its clinical impact is difficult to determine.",
      "management_text": "Caution and clinical monitoring is recommended if propofol is used concomitantly with other agents associated with QT interval prolongation. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25748,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Loperamide",
      "severity": "Moderate",
      "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26426,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Apomorphine",
      "severity": "Moderate",
      "effect": "Apomorphine may cause modest prolongation of the QTc interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if apomorphine is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If taking drugs that also cause CNS or orthostatic effects (e.g., psychotropic drugs like tricyclic antidepressants, phenothiazines, and neuroleptics), patients should be made aware of the possibility of additive effects with apomorphine and counseled to avoid activities requiring mental alertness until they know how these agents affect them.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 28764,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Acetylsalicylic acid",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33924,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Atomoxetine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 35572,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Azithromycin",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 37831,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Buprenorphine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 51163,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 54043,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ciprofloxacin",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 66133,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Clofazimine",
      "severity": "Moderate",
      "effect": "Clofazimine may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if clofazimine is used in combination with other drugs that can prolong the QT interval. Consider monitoring electrocardiograms, particularly in patients receiving clofazimine dosages greater than 100 mg/day, and discontinue QT-prolonging medications if clinically significant ventricular arrhythmia is noted or if QTcF interval >=500 ms is observed. If syncope occurs, obtain an ECG to detect QT prolongation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 70356,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Prochlorperazine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73971,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Didanosine",
      "severity": "Moderate",
      "effect": "INTERVAL: Concomitant administration with didanosine buffered tablets or pediatric oral solution may reduce the oral bioavailability of lomefloxacin and other quinolone antibiotics. The mechanism is reduced quinolone absorption due to chelation with metallic cations from buffering agents and antacids used in certain formulations of didanosine.",
      "management_text": "Lomefloxacin should be administered at least 2 hours before or 4 hours after didanosine buffered tablets or pediatric oral solution, and patients should be monitored for potentially decreased antimicrobial efficacy during concomitant therapy. Didanosine buffered powder for oral solution, which uses a citrate-phosphate buffer, and the delayed-release capsules, which are not buffered, are not expected to cause this interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 86307,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Donepezil",
      "severity": "Moderate",
      "effect": "Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.",
      "management_text": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 90285,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 95618,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Naproxen",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 103206,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Palonosetron",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 103753,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 104715,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Trazodone",
      "severity": "Moderate",
      "effect": "Trazodone may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Coadministration of trazodone with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Trazodone should also not be used in patients with risk factors for QT prolongation. Hypokalemia and hypomagnesemia should be corrected prior to initiation of trazodone treatment and periodically monitored. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. When trazodone is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105109,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Methotrexate",
      "severity": "Moderate",
      "effect": "Coadministration with ciprofloxacin or other quinolones may increase the plasma concentrations of methotrexate. The exact mechanism of interaction is unknown but may involve competitive inhibition of the renal tubular secretion of methotrexate.",
      "management_text": "Caution is advised if quinolones must be used with methotrexate. The authors of the case report recommend that ciprofloxacin and related antibiotics not be coadministered with high-dose methotrexate. During concomitant use, patients should be monitored for altered pharmacologic effects of both drugs and the dosage(s) adjusted accordingly if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 106161,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Pentamidine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107028,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Dextropropoxyphene",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 108944,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sevelamer",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of sevelamer hydrochloride may decrease the oral bioavailability of ciprofloxacin and other quinolones, potentially reducing antibiotic efficacy and increasing the risk of bacterial resistance. The proposed mechanism is reduced quinolone absorption due to chelation with the protonated amine groups of sevelamer in the intestine.",
      "management_text": "Oral quinolone antibiotics should not be administered simultaneously with sevelamer hydrochloride. The optimal length of time needed to separate ingestion of these drugs is currently unknown. Based on the fact that it took up to 4 hours to achieve ciprofloxacin Cmax in all 15 volunteers of the study, the authors suggested a separation time of at least 4 hours between sevelamer and ciprofloxacin administration to reduce the likelihood of a significant interaction, particularly in patients with end-stage renal disease whose gastrointestinal motility may be slowed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 109720,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Risperidone",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 110348,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Tamoxifen",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 112181,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Vardenafil",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 112589,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Mycophenolate mofetil",
      "severity": "Moderate",
      "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.",
      "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 124922,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Nabumetone",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 125415,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Maprotiline",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 134827,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Mefenamic acid",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 136100,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Mefloquine",
      "severity": "Moderate",
      "effect": "Mefloquine is a myocardial depressant and can cause ECG abnormalities. Theoretically, coadministration with other agents that can affect cardiac conduction (e.g., antiarrhythmic agents, beta blockers, calcium channel blockers, certain antihistamines, tricyclic antidepressants, phenothiazines, some neuroleptics) may result in additive effects and increased risk of ventricular arrhythmias including ventricular tachycardia and torsade de pointes.",
      "management_text": "Caution and clinical monitoring are recommended if mefloquine is used in combination with other drugs that can prolong the QT interval or otherwise affect cardiac conduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes or other arrhythmia such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 136293,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Meloxicam",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 136565,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Orciprenaline",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 137675,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Methoxsalen",
      "severity": "Moderate",
      "effect": "Concomitant use of methoxsalen with other known photosensitizing agents may increase the risk of photosensitivity reactions. These agents include anthralin, coal tar or coal tar derivatives, griseofulvin, hypericin extracts (e.g., St John's Wort), fluoroquinolones, phenothiazines, retinoids, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, sulfonylureas, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal, and methyl orange.",
      "management_text": "Caution is advised and pharmacologic response to methoxsalen therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid sun exposure, even through window glass or cloud cover, for at least 8 hours after methoxsalen ingestion and during the 24 hours following photochemotherapy or photopheresis treatment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 138353,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Miglitol",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 141016,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Mirtazapine",
      "severity": "Moderate",
      "effect": "Available data suggest that mirtazapine may cause mild prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if mirtazapine is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 141313,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Nilutamide",
      "severity": "Moderate",
      "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).",
      "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 144400,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Nortriptyline",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 145773,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Olanzapine",
      "severity": "Moderate",
      "effect": "It is uncertain whether olanzapine causes clinically significant prolongation of the QT interval.",
      "management_text": "Some authorities recommend caution when olanzapine is used with drugs that are known to cause QT prolongation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 146545,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ondansetron",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 147973,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Oxaliplatin",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 148897,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Oxytocin",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 149696,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Pemetrexed",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152016,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Perflutren",
      "severity": "Moderate",
      "effect": "Perflutren lipid microsphere suspension (Definity) has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if perflutren lipid microsphere suspension is used in combination with other drugs that can prolong the QT interval. Please refer to the prescribing information for these drugs for more information. No data are available regarding the effect of perflutren protein-type A microsphere suspension (Optison) on the QT interval of the electrocardiogram.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 152819,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Piroxicam",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 154844,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Porfimer sodium",
      "severity": "Moderate",
      "effect": "Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.",
      "management_text": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 155771,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Protriptyline",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 158299,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Quinine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 159173,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ranolazine",
      "severity": "Moderate",
      "effect": "Ranolazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if ranolazine is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of ranolazine, the maximum recommended dosage of 1000 mg twice daily should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Ranolazine is contraindicated in patients with liver cirrhosis because of the profound effect on QT prolongation in this population.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 159747,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Rosiglitazone",
      "severity": "Moderate",
      "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.",
      "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 162874,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Salmeterol",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 163997,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sorafenib",
      "severity": "Moderate",
      "effect": "Sorafenib has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is recommended if sorafenib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting sorafenib therapy and periodically during treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166898,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sucralfate",
      "severity": "Moderate",
      "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 167566,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sulindac",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 167748,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Tacrolimus",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 168258,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Telithromycin",
      "severity": "Moderate",
      "effect": "Telithromycin has the potential to prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if telithromycin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation may increase with increasing plasma concentrations of telithromycin, the recommended dosage should not be exceeded, particularly in patients with renal or hepatic impairment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 169387,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Tizanidine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 172111,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Trimipramine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 174263,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Vasopressin",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 175399,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Venlafaxine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 175810,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Verteporfin",
      "severity": "Moderate",
      "effect": "Concomitant use of verteporfin with other known photosensitizing agents may increase the risk of photosensitivity reactions. Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John's Wort).",
      "management_text": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid exposure of skin or eyes to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 5 days after administration of verteporfin.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 175961,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Voriconazole",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 176436,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Entecavir",
      "severity": "Moderate",
      "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 177904,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Etodolac",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 180877,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Fenoprofen",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 182145,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 183036,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 183581,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Flurbiprofen",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 183711,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Flutamide",
      "severity": "Moderate",
      "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).",
      "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 183798,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Foscarnet",
      "severity": "Moderate",
      "effect": "Limited data suggest that coadministration of foscarnet and ciprofloxacin may potentiate the risk of seizures. Both agents are individually epileptogenic and may have additive effects when combined. Specifically, foscarnet can decrease the seizure threshold by chelating ionized calcium and magnesium, while ciprofloxacin inhibits gamma-aminobutyric acid (GABA).",
      "management_text": "Caution is advised during coadministration of foscarnet and ciprofloxacin, particularly in elderly patients and those with renal impairment, electrolyte and metabolic abnormalities, or underlying neurologic disorders. The same precaution may be applicable during therapy with other quinolones, although clinical data are lacking.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 184289,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Galantamine",
      "severity": "Moderate",
      "effect": "Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.",
      "management_text": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 184944,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Goserelin",
      "severity": "Moderate",
      "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).",
      "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 186252,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Granisetron",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 186313,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 187191,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188145,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 188475,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Amoxapine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 189078,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Chlorpromazine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190031,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Diflunisal",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 190561,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Meclofenamic acid",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 192471,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Perphenazine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193094,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Terbutaline",
      "severity": "Moderate",
      "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.",
      "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193787,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Tolmetin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 193995,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Trifluoperazine",
      "severity": "Moderate",
      "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.",
      "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 194076,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Chromium picolinate",
      "severity": "Moderate",
      "effect": "Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics.  Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc.  The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.",
      "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.  When coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering fluoroquinolone antibiotics at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.  Please consult individual product labeling for specific recommendations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 249965,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Abarelix",
      "severity": "Moderate",
      "effect": "Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 287865,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Bifidobacterium longum infantis",
      "severity": "Moderate",
      "effect": "Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.",
      "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 295644,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Paclitaxel",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 1932,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Busulfan",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 51902,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Capecitabine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 55343,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Docetaxel",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 89478,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Doxorubicin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 91974,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sulfamethoxazole",
      "severity": "Minor",
      "effect": "Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 113146,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Mitoxantrone",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 123479,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Lurbinectedin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 134086,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Melphalan",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 136724,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Mercaptopurine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 137538,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Procarbazine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 157369,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Thiotepa",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 171045,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Fludarabine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 183142,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Topotecan",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 186869,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Hydroxyurea",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 187119,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Idarubicin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 187521,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ifosfamide",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 187719,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Probenecid",
      "severity": "Minor",
      "effect": "Probenecid has been shown to interfere with the urinary excretion of certain quinolone antibiotics, resulting in increased plasma quinolone concentrations in some cases. The clinical relevance of this interaction is unknown but may be greater for quinolones that undergo significant tubular secretion via the renal anion transporter system such as cinoxacin, ciprofloxacin, enoxacin, gemifloxacin, nalidixic acid, and norfloxacin.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 190198,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Cytarabine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 190352,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Sacituzumab govitecan",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 247067,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Melphalan flufenamide",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 286302,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Plicamycin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 287894,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Aldesleukin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 13094,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Altretamine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 19792,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Bleomycin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 45410,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Bumetanide",
      "severity": "Minor",
      "effect": "The plasma concentration of lomefloxacin following administration of furosemide has been reported to be higher than after lomefloxacin alone. The area under the curve of lomefloxacin was increased and the total and renal clearances of lomefloxacin were decreased. A similar interaction may occur if other quinolones are administered with other loop diuretics. The loop diuretic may decrease the renal clearance of the quinolone by competing for tubular secretion.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 50700,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Carboplatin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 57546,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Carmustine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 59121,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Chlorambucil",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 62127,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Cisplatin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 66631,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Clofarabine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 70072,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Cyclophosphamide",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 76748,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Dactinomycin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 78138,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Daunorubicin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 80648,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Denileukin diftitox",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 83055,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Irinotecan",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 119207,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Vincristine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 135263,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Mechlorethamine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 135489,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Metronidazole",
      "severity": "Minor",
      "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 139615,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Mitomycin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 141547,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Pentostatin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 152482,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Streptozocin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 167432,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Temozolomide",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 169795,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Teniposide",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 170139,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Tioguanine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 170941,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Torasemide",
      "severity": "Minor",
      "effect": "The plasma concentration of lomefloxacin following administration of furosemide has been reported to be higher than after lomefloxacin alone. The area under the curve of lomefloxacin was increased and the total and renal clearances of lomefloxacin were decreased. A similar interaction may occur if other quinolones are administered with other loop diuretics. The loop diuretic may decrease the renal clearance of the quinolone by competing for tubular secretion.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 173100,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Tretinoin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 173679,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Vinorelbine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 176212,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Epirubicin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 178398,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Etacrynic acid",
      "severity": "Minor",
      "effect": "The plasma concentration of lomefloxacin following administration of furosemide has been reported to be higher than after lomefloxacin alone. The area under the curve of lomefloxacin was increased and the total and renal clearances of lomefloxacin were decreased. A similar interaction may occur if other quinolones are administered with other loop diuretics. The loop diuretic may decrease the renal clearance of the quinolone by competing for tubular secretion.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 180471,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Etoposide",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 181022,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Floxuridine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 182950,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Fluorouracil",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 183399,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Minor",
      "effect": "The plasma concentration of lomefloxacin following administration of furosemide has been reported to be higher than after lomefloxacin alone. The area under the curve of lomefloxacin was increased and the total and renal clearances of lomefloxacin were decreased. A similar interaction may occur if other quinolones are administered with other loop diuretics. The loop diuretic may decrease the renal clearance of the quinolone by competing for tubular secretion.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 184766,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Gemcitabine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 185168,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Gemtuzumab ozogamicin",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 185340,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Dacarbazine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 190391,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Vinblastine",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 194317,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Brexucabtagene autoleucel",
      "severity": "Minor",
      "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.",
      "management_text": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics.  The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.  In six patients with newly diagnosed hematologic malignancy, treatment with various antineoplastic agents (cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, prednisolone, vincristine) decreased the mean peak serum concentration (Cmax) and area under the concentration-time curve (AUC 0 to 4 hours) of ciprofloxacin by approximately 46% each.  Data are not available for other quinolone antibiotics.",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 259728,
      "ingredient1": "Lomefloxacin"
    },
    {
      "ingredient2": "Ceritinib",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 61491,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Certolizumab pegol",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 61784,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Cobicistat",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 72920,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Deferiprone",
      "severity": "Major",
      "effect": "Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Deferiprone alone can cause agranulocytosis, which may be preceded by neutropenia.",
      "management_text": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided. Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81956,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Boceprevir",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173177,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Enzalutamide",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Given the potential for diminished pharmacologic effects of trabectedin in the presence of potent CYP450 3A4 inducers, concomitant use should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173194,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fingolimod",
      "severity": "Major",
      "effect": "Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.",
      "management_text": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173212,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Golimumab",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173234,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Idelalisib",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173241,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Troleandomycin",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173297,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Tucatinib",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173300,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Typhoid vaccine (live)",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173302,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Upadacitinib",
      "severity": "Major",
      "effect": "Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.",
      "management_text": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173303,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Varicella Zoster Vaccine (Recombinant)",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173307,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Yellow Fever Vaccine",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173315,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Adalimumab",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 9392,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Given the potential for diminished pharmacologic effects of trabectedin in the presence of potent CYP450 3A4 inducers, concomitant use should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 56698,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Cladribine",
      "severity": "Major",
      "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.",
      "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 67656,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 68122,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Major",
      "effect": "Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.",
      "management_text": "Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function. Agents that may be significantly myelotoxic include antineoplastic drugs, some anticonvulsant and antirheumatic medications, albendazole, chloramphenicol, colchicine, dapsone, interferons, linezolid, pentamidine, procainamide, and zidovudine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 72679,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Conivaptan",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 74497,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Delavirdine",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 82996,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 121195,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Amprenavir",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173168,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Etanercept",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173199,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fosamprenavir",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173220,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fosphenytoin",
      "severity": "Major",
      "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Given the potential for diminished pharmacologic effects of trabectedin in the presence of potent CYP450 3A4 inducers, concomitant use should generally be avoided.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173223,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Indinavir",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173243,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Infliximab",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173245,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Voriconazole",
      "severity": "Major",
      "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of trabectedin during and for 2 weeks after treatment with itraconazole. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 173313,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Abametapir (topical)",
      "severity": "Moderate",
      "effect": "Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450 3A4, CYP450 2B6, and CYP450 1A2 isoenzymes and increase their systemic concentrations. The proposed mechanism is high and prolonged systemic exposure to the metabolite abametapir carboxyl, which has been shown to be an in vitro inhibitor of CYP450 3A4, CYP450 2B6, and CYP450 1A2.",
      "management_text": "Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion. If abametapir is used, monitor for increased toxicity of the CYP450 3A4, CYP450 2B6, and/or CYP450 1A2 substrate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 847,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Abemaciclib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 1272,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Abiraterone",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 1633,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Clostridium tetani toxoid antigen (formaldehyde inactivated)",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 8589,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Afatinib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10636,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Alectinib",
      "severity": "Moderate",
      "effect": "The risk of rhabdomyolysis may be increased during coadministration of trabectedin with other agents that are also associated with this toxicity, such as colchicine, alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin. The risk of liver injury may be increased during coadministration of trabectedin with other potentially hepatotoxic agents, including alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin.",
      "management_text": "Caution is advised when trabectedin is used with other agents associated with rhabdomyolysis. Patients should be advised to seek medical attention if they experience unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Caution is advised when trabectedin is used with other agents that are potentially hepatotoxic. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13382,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Ambrisentan",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20478,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Binimetinib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 44011,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Blinatumomab",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 45586,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Bosutinib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 46804,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Brentuximab vedotin",
      "severity": "Moderate",
      "effect": "Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.",
      "management_text": "The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 47280,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Cabazitaxel",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 52848,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Calaspargase pegol",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 53629,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Canakinumab",
      "severity": "Moderate",
      "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.",
      "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 54703,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Cannabidiol",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 55231,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Capmatinib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 55722,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Carfilzomib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 58359,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Cenobamate",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60972,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Chenodeoxycholic acid",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 62053,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)",
      "severity": "Moderate",
      "effect": "There are no data regarding the use of live, attenuated cholera vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.",
      "management_text": "The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64727,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Cobimetinib",
      "severity": "Moderate",
      "effect": "The risk of rhabdomyolysis may be increased during coadministration of trabectedin with other agents that are also associated with this toxicity, such as colchicine, alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin. The risk of liver injury may be increased during coadministration of trabectedin with other potentially hepatotoxic agents, including alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin.",
      "management_text": "Caution is advised when trabectedin is used with other agents associated with rhabdomyolysis. Patients should be advised to seek medical attention if they experience unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Caution is advised when trabectedin is used with other agents that are potentially hepatotoxic. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73121,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Crizotinib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Reversible, acute increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have occurred frequently in patients treated with trabectedin alone or with pegylated liposomal doxorubicin in clinical trials.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.g., azole antifungal agents; bicalutamide; cyclosporine (high dosages); dronedarone; macrolide antibiotics; protein kinase inhibitors; zafirlukast). Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop. Trabectedin must not be used in patients with elevated bilirubin at the time of initiation of cycle. Elevated liver function tests should be managed with treatment interruption, dosage reduction, or permanent discontinuation depending on the severity and duration of abnormality.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 76104,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Dabrafenib",
      "severity": "Moderate",
      "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.",
      "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 77866,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Denosumab",
      "severity": "Moderate",
      "effect": "Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the receptor activator of nuclear factor kappa-B ligand (RANKL), which is expressed on activated T and B lymphocytes and in lymph nodes. Thus, denosumab alone may increase the risk of infections.",
      "management_text": "Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. The need for continued denosumab therapy should be assessed when serious infections occur during treatment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 83237,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Dimethyl fumarate",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 87293,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Dinutuximab",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 87427,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Diroximel fumarate",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 88135,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Duvelisib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Reversible, acute increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have occurred frequently in patients treated with trabectedin alone or with pegylated liposomal doxorubicin in clinical trials.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.g., azole antifungal agents; bicalutamide; cyclosporine (high dosages); dronedarone; macrolide antibiotics; protein kinase inhibitors; zafirlukast). Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop. Trabectedin must not be used in patients with elevated bilirubin at the time of initiation of cycle. Elevated liver function tests should be managed with treatment interruption, dosage reduction, or permanent discontinuation depending on the severity and duration of abnormality.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 94659,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Elagolix",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 96569,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Ivacaftor",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Reversible, acute increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have occurred frequently in patients treated with trabectedin alone or with pegylated liposomal doxorubicin in clinical trials.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.g., azole antifungal agents; bicalutamide; cyclosporine (high dosages); dronedarone; macrolide antibiotics; protein kinase inhibitors; zafirlukast). Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop. Trabectedin must not be used in patients with elevated bilirubin at the time of initiation of cycle. Elevated liver function tests should be managed with treatment interruption, dosage reduction, or permanent discontinuation depending on the severity and duration of abnormality.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 97245,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Eltrombopag",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 97726,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Enfortumab vedotin",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 99670,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Inotersen",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 115267,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Inotuzumab ozogamicin",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 115475,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Ipilimumab",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 119016,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Isavuconazonium",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 119679,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Human adenovirus e serotype 4 strain cl-68578 antigen",
      "severity": "Moderate",
      "effect": "There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.",
      "management_text": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173166,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Berotralstat",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173175,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Bifidobacterium longum infantis",
      "severity": "Moderate",
      "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173176,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Candida albicans",
      "severity": "Moderate",
      "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173180,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Coccidioides immitis spherule",
      "severity": "Moderate",
      "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173186,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Echinacea",
      "severity": "Moderate",
      "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.",
      "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173190,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Elotuzumab",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173192,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Entrectinib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173193,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Eribulin",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173196,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Eslicarbazepine",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173198,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Etravirine",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173205,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fedratinib",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173207,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fenofibric acid",
      "severity": "Moderate",
      "effect": "The risk of rhabdomyolysis may be increased during coadministration of trabectedin with other agents that are also associated with this toxicity, such as colchicine, alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin. The risk of liver injury may be increased during coadministration of trabectedin with other potentially hepatotoxic agents, including alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin.",
      "management_text": "Caution is advised when trabectedin is used with other agents associated with rhabdomyolysis. Patients should be advised to seek medical attention if they experience unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Caution is advised when trabectedin is used with other agents that are potentially hepatotoxic. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173209,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fosaprepitant",
      "severity": "Moderate",
      "effect": "Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of chemotherapeutic agents that are primarily metabolized by CYP450 3A4. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant. In general, the effect of aprepitant on the pharmacokinetics of CYP450 3A4 substrates is expected to be greater when the substrates are administered orally as opposed to intravenously and may be altered following prolonged administration.",
      "management_text": "Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials. The potential for increased systemic toxicities of these agents should be considered. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173221,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fostamatinib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173224,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Gilteritinib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173230,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Givosiran",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173231,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Goldenseal",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173233,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Hepatitis A Vaccine",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173237,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Hepatitis B Vaccine (Recombinant)",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173238,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Human papillomavirus type 11 L1 capsid protein antigen",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173239,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173246,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173247,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Diiodohydroxyquinoline",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173251,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Trichophyton mentagrophytes",
      "severity": "Moderate",
      "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173294,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Tuberculin purified protein derivative",
      "severity": "Moderate",
      "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173299,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Ustekinumab",
      "severity": "Moderate",
      "effect": "The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.",
      "management_text": "Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173304,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Vemurafenib",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173308,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Voxelotor",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173314,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fosnetupitant",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 191176,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Dalfopristin",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors.  Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 297689,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Zidovudine",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 473,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Isotretinoin",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 2163,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Acitretin",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 7085,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10449,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12832,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Aldesleukin",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13265,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Alefacept",
      "severity": "Moderate",
      "effect": "The use of alefacept with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.",
      "management_text": "Patients receiving other immunosuppressive or myelosuppressive agents or phototherapy should not be treated with alefacept because of the possibility of excessive immunosuppression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13644,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Alemtuzumab",
      "severity": "Moderate",
      "effect": "The use of alemtuzumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Alemtuzumab alone may cause severe and prolonged myelosuppression, lymphopenia, and rarely, fatal bone marrow aplasia/hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia. Serious, sometimes fatal opportunistic infections have been reported, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.",
      "management_text": "Caution is advised if alemtuzumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. The manufacturer recommends that single doses of alemtuzumab not exceed 30 mg and cumulative weekly doses not exceed 90 mg, since higher dosages are associated with an increased incidence of pancytopenia. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13920,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Diclofenac (topical)",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20199,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Aminosalicylic acid",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 21317,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 21866,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 23640,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Amobarbital",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24239,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Clavulanic acid",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24323,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Anakinra",
      "severity": "Moderate",
      "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.",
      "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25248,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fenofibrate",
      "severity": "Moderate",
      "effect": "The risk of rhabdomyolysis may be increased during coadministration of trabectedin with other agents that are also associated with this toxicity, such as colchicine, alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin. The risk of liver injury may be increased during coadministration of trabectedin with other potentially hepatotoxic agents, including alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin.",
      "management_text": "Caution is advised when trabectedin is used with other agents associated with rhabdomyolysis. Patients should be advised to seek medical attention if they experience unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Caution is advised when trabectedin is used with other agents that are potentially hepatotoxic. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26714,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 28525,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39499,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Bexarotene",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 43377,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Bicalutamide",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Reversible, acute increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have occurred frequently in patients treated with trabectedin alone or with pegylated liposomal doxorubicin in clinical trials.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.g., azole antifungal agents; bicalutamide; cyclosporine (high dosages); dronedarone; macrolide antibiotics; protein kinase inhibitors; zafirlukast). Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop. Trabectedin must not be used in patients with elevated bilirubin at the time of initiation of cycle. Elevated liver function tests should be managed with treatment interruption, dosage reduction, or permanent discontinuation depending on the severity and duration of abnormality.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 43682,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Bortezomib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 46131,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Bosentan",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 46460,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Butalbital",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 52219,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 56095,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Carboplatin",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57631,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Diltiazem",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 58148,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Carmustine",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 59183,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Chloramphenicol",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 62500,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Chloroquine",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 63262,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Chlorzoxazone",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64460,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Cimetidine",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 65803,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Ciprofloxacin",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 66351,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Cisplatin",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 66731,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Clofarabine",
      "severity": "Moderate",
      "effect": "The liver is a known target organ for clofarabine toxicity, and concomitant use of other potentially hepatotoxic agents may increase the risk of liver injury. Severe and fatal hepatotoxicity has occurred with the use of clofarabine alone.",
      "management_text": "Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Hepatic function should be monitored during clofarabine administration, and therapy discontinued if grade 3 to 4 liver enzyme or bilirubin elevations occur. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 70242,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Colchicine",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73528,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Verapamil",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75656,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Cyclosporine",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Reversible, acute increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have occurred frequently in patients treated with trabectedin alone or with pegylated liposomal doxorubicin in clinical trials.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.g., azole antifungal agents; bicalutamide; cyclosporine (high dosages); dronedarone; macrolide antibiotics; protein kinase inhibitors; zafirlukast). Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop. Trabectedin must not be used in patients with elevated bilirubin at the time of initiation of cycle. Elevated liver function tests should be managed with treatment interruption, dosage reduction, or permanent discontinuation depending on the severity and duration of abnormality.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 77287,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Danazol",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78509,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Dantrolene",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78693,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Darunavir",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 80016,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Dasatinib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 80481,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Deferasirox",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81754,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Didanosine",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 86377,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Disulfiram",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 89109,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Valproic acid",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 89351,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Docetaxel",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 89608,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Dronedarone",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Reversible, acute increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have occurred frequently in patients treated with trabectedin alone or with pegylated liposomal doxorubicin in clinical trials.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.g., azole antifungal agents; bicalutamide; cyclosporine (high dosages); dronedarone; macrolide antibiotics; protein kinase inhibitors; zafirlukast). Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop. Trabectedin must not be used in patients with elevated bilirubin at the time of initiation of cycle. Elevated liver function tests should be managed with treatment interruption, dosage reduction, or permanent discontinuation depending on the severity and duration of abnormality.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 92799,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 93937,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Reversible, acute increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have occurred frequently in patients treated with trabectedin alone or with pegylated liposomal doxorubicin in clinical trials.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.g., azole antifungal agents; bicalutamide; cyclosporine (high dosages); dronedarone; macrolide antibiotics; protein kinase inhibitors; zafirlukast). Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop. Trabectedin must not be used in patients with elevated bilirubin at the time of initiation of cycle. Elevated liver function tests should be managed with treatment interruption, dosage reduction, or permanent discontinuation depending on the severity and duration of abnormality.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 95830,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Efavirenz",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 96284,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Emtricitabine",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98360,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98799,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Interferon alfa-2b",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 117481,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Interferon beta-1a",
      "severity": "Moderate",
      "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.",
      "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 117649,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Interferon beta-1b",
      "severity": "Moderate",
      "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.",
      "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 117822,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Interferon gamma-1b",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 117898,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Hydralazine",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 120507,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Vincristine",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 135366,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Aminoglutethimide",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173167,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Bromfenac",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173178,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Butabarbital",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173179,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Caspofungin",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173181,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Cerivastatin",
      "severity": "Moderate",
      "effect": "The risk of rhabdomyolysis may be increased during coadministration of trabectedin with other agents that are also associated with this toxicity, such as colchicine, alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin. The risk of liver injury may be increased during coadministration of trabectedin with other potentially hepatotoxic agents, including alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin.",
      "management_text": "Caution is advised when trabectedin is used with other agents associated with rhabdomyolysis. Patients should be advised to seek medical attention if they experience unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Caution is advised when trabectedin is used with other agents that are potentially hepatotoxic. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173182,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Clofibrate",
      "severity": "Moderate",
      "effect": "The risk of rhabdomyolysis may be increased during coadministration of trabectedin with other agents that are also associated with this toxicity, such as colchicine, alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin. The risk of liver injury may be increased during coadministration of trabectedin with other potentially hepatotoxic agents, including alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin.",
      "management_text": "Caution is advised when trabectedin is used with other agents associated with rhabdomyolysis. Patients should be advised to seek medical attention if they experience unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Caution is advised when trabectedin is used with other agents that are potentially hepatotoxic. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173184,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Clotrimazole",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173185,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Cytarabine",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173187,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Dacarbazine",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173188,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Dapsone",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173189,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Efalizumab",
      "severity": "Moderate",
      "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.",
      "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173191,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Epirubicin",
      "severity": "Moderate",
      "effect": "The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes elimination through the hepatobiliary system.",
      "management_text": "Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173195,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Erlotinib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173197,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Ethambutol",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173200,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Ethionamide",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173201,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Ethotoin",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173202,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Etodolac",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173203,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Etoposide",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173204,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Febuxostat",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173206,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Felbamate",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173208,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fenoprofen",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173210,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Filgrastim",
      "severity": "Moderate",
      "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.",
      "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173211,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Reversible, acute increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have occurred frequently in patients treated with trabectedin alone or with pegylated liposomal doxorubicin in clinical trials.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.g., azole antifungal agents; bicalutamide; cyclosporine (high dosages); dronedarone; macrolide antibiotics; protein kinase inhibitors; zafirlukast). Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop. Trabectedin must not be used in patients with elevated bilirubin at the time of initiation of cycle. Elevated liver function tests should be managed with treatment interruption, dosage reduction, or permanent discontinuation depending on the severity and duration of abnormality.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173213,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fludarabine",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173214,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fluoxymesterone",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173215,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Flurbiprofen",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173216,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Flutamide",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173217,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fluvastatin",
      "severity": "Moderate",
      "effect": "The risk of rhabdomyolysis may be increased during coadministration of trabectedin with other agents that are also associated with this toxicity, such as colchicine, alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin. The risk of liver injury may be increased during coadministration of trabectedin with other potentially hepatotoxic agents, including alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin.",
      "management_text": "Caution is advised when trabectedin is used with other agents associated with rhabdomyolysis. Patients should be advised to seek medical attention if they experience unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Caution is advised when trabectedin is used with other agents that are potentially hepatotoxic. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173218,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fluvoxamine",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173219,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Fosinopril",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173222,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Ganciclovir",
      "severity": "Moderate",
      "effect": "The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.",
      "management_text": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173225,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Gefitinib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173226,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Gemcitabine",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173227,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Gemfibrozil",
      "severity": "Moderate",
      "effect": "The risk of rhabdomyolysis may be increased during coadministration of trabectedin with other agents that are also associated with this toxicity, such as colchicine, alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin. The risk of liver injury may be increased during coadministration of trabectedin with other potentially hepatotoxic agents, including alectinib, cobimetinib, statins, fibric acid derivatives, and lipid-lowering doses of niacin.",
      "management_text": "Caution is advised when trabectedin is used with other agents associated with rhabdomyolysis. Patients should be advised to seek medical attention if they experience unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Caution is advised when trabectedin is used with other agents that are potentially hepatotoxic. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173228,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Gemtuzumab ozogamicin",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173229,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Grepafloxacin",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173235,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Griseofulvin",
      "severity": "Moderate",
      "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.",
      "management_text": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173236,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173240,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Imatinib",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Reversible, acute increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have occurred frequently in patients treated with trabectedin alone or with pegylated liposomal doxorubicin in clinical trials.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.g., azole antifungal agents; bicalutamide; cyclosporine (high dosages); dronedarone; macrolide antibiotics; protein kinase inhibitors; zafirlukast). Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop. Trabectedin must not be used in patients with elevated bilirubin at the time of initiation of cycle. Elevated liver function tests should be managed with treatment interruption, dosage reduction, or permanent discontinuation depending on the severity and duration of abnormality.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173242,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173244,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Interferon alfa-2a, Recombinant",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173248,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Interferon alfa-n1",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173249,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Interferon alfacon-1",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173250,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Isoniazid",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173252,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Tretinoin",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173293,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Trimetrexate",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173295,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Troglitazone",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173296,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Trovafloxacin",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173298,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Valdecoxib",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173305,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Valganciclovir",
      "severity": "Moderate",
      "effect": "The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.",
      "management_text": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173306,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Vinblastine",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173309,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Vinorelbine",
      "severity": "Moderate",
      "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.",
      "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173311,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Vitamin E",
      "severity": "Moderate",
      "effect": "The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.",
      "management_text": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173312,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Zafirlukast",
      "severity": "Moderate",
      "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Reversible, acute increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have occurred frequently in patients treated with trabectedin alone or with pegylated liposomal doxorubicin in clinical trials.",
      "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.g., azole antifungal agents; bicalutamide; cyclosporine (high dosages); dronedarone; macrolide antibiotics; protein kinase inhibitors; zafirlukast). Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop. Trabectedin must not be used in patients with elevated bilirubin at the time of initiation of cycle. Elevated liver function tests should be managed with treatment interruption, dosage reduction, or permanent discontinuation depending on the severity and duration of abnormality.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173316,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Zalcitabine",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173317,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Zileuton",
      "severity": "Moderate",
      "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.",
      "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 173318,
      "ingredient1": "Trabectedin"
    },
    {
      "ingredient2": "Dextropropoxyphene",
      "severity": "Major",
      "effect": "Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene. Misuse of propoxyphene, either alone or in combination with other CNS depressants, has been a major cause of drug-related deaths, particularly in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Pharmacokinetically, propoxyphene is an inhibitor of CYP450 2D6 and may increase the plasma concentrations of many psychotropic agents that are metabolized by the isoenzyme such as phenothiazines, haloperidol, risperidone, phenobarbital, and some tricyclic antidepressants and serotonin reuptake inhibitors.",
      "management_text": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Dosage reductions may be appropriate. Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects. Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 57237,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 2243,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Chlorpheniramine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 3564,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Dihydrocodeine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 4620,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Dichloralphenazone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5470,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Moderate",
      "effect": "Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents. Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12475,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Alfentanil",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 14156,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Fosphenytoin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15159,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Gabapentin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15574,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Amantadine",
      "severity": "Moderate",
      "effect": "The anticholinergic-like adverse effects of amantadine may be potentiated by agents with anticholinergic properties such as antihistamines, antispasmodics, class IA antiarrhythmics, neuroleptics, phenothiazines, skeletal muscle relaxants, and tricyclic antidepressants. The cumulative parasympatholytic effects of these agents may produce paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.",
      "management_text": "Caution is advised when amantadine is used in combination with anticholinergic agents, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations. Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them. A reduction in anticholinergic and/or amantadine dosage may be necessary if excessive adverse effects develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20006,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Amobarbital",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 23880,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Glycopyrronium",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50387,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Cariprazine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57070,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Cenobamate",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57072,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Clofedanol",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57073,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Chloral hydrate",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57074,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Chlorcyclizine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57075,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Chlormezanone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57077,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Chlorphenesin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57078,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Clidinium",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57083,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Clomipramine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57085,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Clonazepam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57086,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Coccidioides immitis spherule",
      "severity": "Moderate",
      "effect": "INTERVAL: Antihistamines may diminish the response to diagnostic skin test antigens. Falsely insignificant or false-negative results may occur in such patients.",
      "management_text": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57090,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Cyclizine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57091,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Cyclobenzaprine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57092,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Dantrolene",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57094,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Demecarium (ophthalmic)",
      "severity": "Moderate",
      "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.",
      "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57096,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Desipramine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57097,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Desvenlafaxine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57098,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Deutetrabenazine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57099,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Dezocine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57102,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57103,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Dicyclomine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57104,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Dimenhydrinate",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57105,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Diphenhydramine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57106,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Donepezil",
      "severity": "Moderate",
      "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.",
      "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57109,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Doxepin",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57110,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Echothiophate (ophthalmic)",
      "severity": "Moderate",
      "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.",
      "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57116,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Eluxadoline",
      "severity": "Moderate",
      "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.",
      "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57117,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Escitalopram",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57119,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Esketamine",
      "severity": "Moderate",
      "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.",
      "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants. Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting. Patients should be instructed not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57120,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Eslicarbazepine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57121,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Estazolam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57122,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Ethotoin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57126,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Ezogabine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57127,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Felbamate",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57128,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Fesoterodine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57129,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Flavoxate",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57130,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Flibanserin",
      "severity": "Moderate",
      "effect": "The central nervous system (CNS) effects of flibanserin such as somnolence and fatigue may be potentiated by concomitant use of other agents with CNS depressant effects. The risk of CNS depression is increased if flibanserin is taken during waking hours or with alcohol or other CNS depressants.",
      "management_text": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue. Patients should not drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking flibanserin.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57131,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Halazepam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57136,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Diamorphine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57138,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Histamine",
      "severity": "Moderate",
      "effect": "Antihistamines may suppress the patient's response to histamine phosphate. The length of suppression varies and is dependent on the patient, type of antihistamine, and the duration of antihistamine therapy. The duration of suppression may range from 24 hours with chlorpheniramine or up to several weeks with second-generation antihistamines.",
      "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering histamine phosphate to patients treated with antihistamines.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57139,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Hydrocodone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57141,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Ifosfamide",
      "severity": "Moderate",
      "effect": "Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.",
      "management_text": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57144,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57145,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Isocarboxazid",
      "severity": "Moderate",
      "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects. In addition, limited data suggest that MAOIs may potentiate and prolong the anticholinergic effects of antihistamines due to inhibition of catecholamine degradation, which may lead to overstimulation of the sympathetic nervous system.",
      "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided. If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57149,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Iodide I-123",
      "severity": "Moderate",
      "effect": "INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.",
      "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57257,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Iodide I-131",
      "severity": "Moderate",
      "effect": "INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.",
      "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57258,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Alimemazine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57288,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Diphenoxylate",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 87736,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Fenfluramine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 252891,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Difenoxin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 298591,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Homatropine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 300389,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Codeine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5070,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Fluvoxamine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 14641,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Galantamine",
      "severity": "Moderate",
      "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia. These agents may also adversely affect elderly patients in general. Clinically significant mental status changes associated with anticholinergic agents can range from mild cognitive impairment to delirium, and patients with Alzheimer's disease and other dementia are especially sensitive.",
      "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor. For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible. Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered. For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15665,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Cetirizine",
      "severity": "Moderate",
      "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.",
      "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17393,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Alprazolam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 19087,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Amitriptyline",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22284,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Hyoscyamine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25299,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Dextromethorphan",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 44037,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 56223,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Amoxapine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57064,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Carisoprodol",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57071,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Chlordiazepoxide",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57076,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Chlorpromazine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57079,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Chlorzoxazone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57080,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57081,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Clemastine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57082,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Clobazam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57084,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Clonidine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57087,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Clorazepic acid",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57088,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57089,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Cyproheptadine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57093,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Darifenacin",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57095,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Dexbrompheniramine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57100,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Dexmedetomidine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57101,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Disopyramide",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57107,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Doxylamine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57112,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Dronabinol",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57113,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Droperidol",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57114,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57115,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Entacapone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57118,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Eszopiclone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57123,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Ethchlorvynol",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57124,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Ethosuximide",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57125,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57132,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57133,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Flurazepam",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57134,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57137,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Hydromorphone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57142,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57143,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Moderate",
      "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.",
      "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57146,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Ipratropium",
      "severity": "Moderate",
      "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties. The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing. Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.",
      "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide). Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57147,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Isoflurophate (ophthalmic)",
      "severity": "Moderate",
      "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine. The proposed mechanism involves opposing pharmacodynamic action on muscarinic receptor sites in ocular tissue. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose.",
      "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57150,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Hyaluronidase",
      "severity": "Minor",
      "effect": "Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines. These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 57140,
      "ingredient1": "Carbinoxamine"
    },
    {
      "ingredient2": "Givosiran",
      "severity": "Moderate",
      "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.",
      "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 185542,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Indium In-111 oxyquinoline",
      "severity": "Moderate",
      "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.",
      "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 191792,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Colistimethate",
      "severity": "Moderate",
      "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.",
      "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 262860,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Dicoumarol",
      "severity": "Moderate",
      "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists.  Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.",
      "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.  The anticoagulant dose may be adjusted as indicated.  Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 262861,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Ethinylestradiol",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Some investigators believe that antimicrobials interfere with the enterohepatic recirculation of estrogens by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating parent estrogen molecules following first-pass metabolism. It is possible that a small number of women may be more susceptible to contraceptive failure and, consequently, are more sensitive to the effects of antimicrobials on estrogen disposition in vivo, but risk factors or genetic predispositions have yet to be identified.",
      "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. Alternative or additional methods of birth control should be considered during and for at least one week beyond the last dose of short-term antimicrobial therapy, and for at least the initial weeks of long-term antimicrobial therapy when risk may be the greatest.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10702,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Moderate",
      "effect": "Some cephalosporins may occasionally induce a disulfiram-like reaction when coadministered with alcohol. The interaction has been reported for cefamandole, cefoperazone, cefotetan, and moxalactam. These agents contain an N-methylthiotetrazole (NMTT) side chain that may inhibit aldehyde dehydrogenase (ALDH) similar to disulfiram. Following ingestion of alcohol, inhibition of ALDH results in increased concentration of acetaldehyde, the accumulation of which produces an unpleasant physiologic response referred to as the 'disulfiram reaction'. Symptoms include flushing, throbbing in head and neck, throbbing headache, respiratory difficulty, nausea, vomiting, sweating, thirst, chest pain, palpitation, dyspnea, hyperventilation, tachycardia, hypotension, syncope, weakness, vertigo, blurred vision, and confusion. Severe reactions may result in respiratory depression, cardiovascular collapse, arrhythmias, myocardial infarction, acute congestive heart failure, unconsciousness, convulsions, and death.",
      "management_text": "Patients receiving cephalosporins with the NMTT side chain should avoid the concomitant use of alcohol and alcohol-containing products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12482,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Estradiol",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Some investigators believe that antimicrobials interfere with the enterohepatic recirculation of estrogens by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating parent estrogen molecules following first-pass metabolism. It is possible that a small number of women may be more susceptible to contraceptive failure and, consequently, are more sensitive to the effects of antimicrobials on estrogen disposition in vivo, but risk factors or genetic predispositions have yet to be identified.",
      "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. Alternative or additional methods of birth control should be considered during and for at least one week beyond the last dose of short-term antimicrobial therapy, and for at least the initial weeks of long-term antimicrobial therapy when risk may be the greatest.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18483,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Amikacin",
      "severity": "Moderate",
      "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.",
      "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20788,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Chloramphenicol",
      "severity": "Moderate",
      "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.",
      "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 62212,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Entecavir",
      "severity": "Moderate",
      "effect": "Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.",
      "management_text": "Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 177878,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Etacrynic acid",
      "severity": "Moderate",
      "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.",
      "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 180406,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Moderate",
      "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.",
      "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 184716,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Gentamicin",
      "severity": "Moderate",
      "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.",
      "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 191327,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Heparin",
      "severity": "Moderate",
      "effect": "Cefamandole, cefoperazone, and cefotetan contain a methylthiotetrazole (MTT) side chain that may interfere with the biosynthesis of prothrombin. These agents have rarely been associated with bleeding and with significant increases in prothrombin times. These effects may potentiate the effects of heparin. Patients who are elderly, renally impaired, or undernourished appear to be at a greater risk.",
      "management_text": "Usually, no special management is necessary, but the patient should be monitored for bleeding if heparin must be given concurrently. Vitamin K is effective in treating cephalosporin-induced coagulopathies.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 191552,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Anisindione",
      "severity": "Moderate",
      "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists.  Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.",
      "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding.  The anticoagulant dose may be adjusted as indicated.  Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 262859,
      "ingredient1": "Cefoperazone"
    },
    {
      "ingredient2": "Deferiprone",
      "severity": "Major",
      "effect": "Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Deferiprone alone can cause agranulocytosis, which may be preceded by neutropenia.",
      "management_text": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided. Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81337,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Fingolimod",
      "severity": "Major",
      "effect": "Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.",
      "management_text": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81345,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Golimumab",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81348,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Etanercept",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81342,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Infliximab",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81357,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Human adenovirus e serotype 4 strain cl-68578 antigen",
      "severity": "Moderate",
      "effect": "There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.",
      "management_text": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81327,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Denosumab",
      "severity": "Moderate",
      "effect": "Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the receptor activator of nuclear factor kappa-B ligand (RANKL), which is expressed on activated T and B lymphocytes and in lymph nodes. Thus, denosumab alone may increase the risk of infections.",
      "management_text": "Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. The need for continued denosumab therapy should be assessed when serious infections occur during treatment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81338,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Dimethyl fumarate",
      "severity": "Moderate",
      "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.",
      "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81339,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Diroximel fumarate",
      "severity": "Moderate",
      "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.",
      "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81340,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Hepatitis A Vaccine",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81349,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Hepatitis B Vaccine (Recombinant)",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81350,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Human papillomavirus type 11 L1 capsid protein antigen",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81351,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Idelalisib",
      "severity": "Moderate",
      "effect": "The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.",
      "management_text": "Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81354,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81358,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81359,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Isatuximab",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81362,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Doxorubicin",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 270674,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Ibritumomab tiuxetan",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 270681,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Ganciclovir",
      "severity": "Moderate",
      "effect": "The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.",
      "management_text": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15767,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Gemcitabine",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15854,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Anakinra",
      "severity": "Moderate",
      "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.",
      "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25062,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Daunorubicin",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 80546,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Efalizumab",
      "severity": "Moderate",
      "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.",
      "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81341,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Etoposide",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81343,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Filgrastim",
      "severity": "Moderate",
      "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.",
      "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81344,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Floxuridine",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81346,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Fluorouracil",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81347,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Hydroxyurea",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81352,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Idarubicin",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81353,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Ifosfamide",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81355,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Imatinib",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81356,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Interferon alfa-2a, Recombinant",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81360,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Interferon alfa-2b",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81361,
      "ingredient1": "Decitabine"
    },
    {
      "ingredient2": "Indium In-111 oxyquinoline",
      "severity": "Moderate",
      "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.",
      "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60358,
      "ingredient1": "Ceftaroline fosamil"
    },
    {
      "ingredient2": "Ethinylestradiol",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Some investigators believe that antimicrobials interfere with the enterohepatic recirculation of estrogens by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating parent estrogen molecules following first-pass metabolism. It is possible that a small number of women may be more susceptible to contraceptive failure and, consequently, are more sensitive to the effects of antimicrobials on estrogen disposition in vivo, but risk factors or genetic predispositions have yet to be identified.",
      "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. Alternative or additional methods of birth control should be considered during and for at least one week beyond the last dose of short-term antimicrobial therapy, and for at least the initial weeks of long-term antimicrobial therapy when risk may be the greatest.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10708,
      "ingredient1": "Ceftaroline fosamil"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Moderate",
      "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.",
      "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15502,
      "ingredient1": "Ceftaroline fosamil"
    },
    {
      "ingredient2": "Estradiol",
      "severity": "Moderate",
      "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Some investigators believe that antimicrobials interfere with the enterohepatic recirculation of estrogens by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating parent estrogen molecules following first-pass metabolism. It is possible that a small number of women may be more susceptible to contraceptive failure and, consequently, are more sensitive to the effects of antimicrobials on estrogen disposition in vivo, but risk factors or genetic predispositions have yet to be identified.",
      "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. Alternative or additional methods of birth control should be considered during and for at least one week beyond the last dose of short-term antimicrobial therapy, and for at least the initial weeks of long-term antimicrobial therapy when risk may be the greatest.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18489,
      "ingredient1": "Ceftaroline fosamil"
    },
    {
      "ingredient2": "Amikacin",
      "severity": "Moderate",
      "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.",
      "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20794,
      "ingredient1": "Ceftaroline fosamil"
    },
    {
      "ingredient2": "Anisindione",
      "severity": "Moderate",
      "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.",
      "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60352,
      "ingredient1": "Ceftaroline fosamil"
    },
    {
      "ingredient2": "Chloramphenicol",
      "severity": "Moderate",
      "effect": "Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis.",
      "management_text": "The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60353,
      "ingredient1": "Ceftaroline fosamil"
    },
    {
      "ingredient2": "Dicoumarol",
      "severity": "Moderate",
      "effect": "Cephalosporins may potentiate the anticoagulant effects of vitamin K antagonists. Possible mechanisms include inhibited growth of vitamin K-producing intestinal bacteria, inhibited production of vitamin K-dependent clotting factors via a methylthiotetrazole (MTT) side chain (e.g., cefamandole, cefmetazole, cefoperazone, cefotetan), and/or inhibited platelet activity.",
      "management_text": "Prothrombin time and INR should be monitored and the patient closely observed for signs of bleeding. The anticoagulant dose may be adjusted as indicated. Patients should be advised to notify their physicians if they experience any signs or symptoms that may indicate excessive anticoagulation, such as unusual or prolonged bleeding, bruising, coffee ground emesis, change in stool or urine color, headache, dizziness, or weakness.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60355,
      "ingredient1": "Ceftaroline fosamil"
    },
    {
      "ingredient2": "Etacrynic acid",
      "severity": "Moderate",
      "effect": "Limited data suggest that furosemide and possibly other loop diuretics may potentiate the nephrotoxicity of some cephalosporins. The exact mechanism of interaction is unknown, although furosemide has been shown to increase the plasma concentrations and/or reduce the clearance of several cephalosporins such as cephaloridine and ceftazidime.",
      "management_text": "Although data are primarily limited to cephaloridine, which is no longer commercially marketed, caution may be advisable in patients receiving a loop diuretic in combination with other cephalosporins. Renal function should be monitored, particularly when high dosages are used or when these medications are administered in the elderly or patients with preexisting renal impairment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60356,
      "ingredient1": "Ceftaroline fosamil"
    },
    {
      "ingredient2": "Gentamicin",
      "severity": "Moderate",
      "effect": "Coadministration of aminoglycosides and cephalosporins may increase the risk of nephrotoxicity. An increased incidence of nephrotoxicity has been reported during concomitant use of aminoglycosides and some, mostly older cephalosporins (e.g., cefaloridine, cefamandole, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, cephalothin, ceftriaxone). The risk may be greatest in the elderly or patients with preexisting renal impairment, when large doses are used, and during prolonged treatment.",
      "management_text": "The lowest effective dosages of aminoglycosides and cephalosporins should be used when they are prescribed in combination. Renal function should be monitored closely. The same precaution may be applicable when aminoglycosides are administered via irrigation, intrapleurally, intraperitoneally or orally, since aminoglycosides can be systemically absorbed via these routes; however, clinical data are lacking.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60357,
      "ingredient1": "Ceftaroline fosamil"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Major",
      "effect": "Amiodarone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.",
      "management_text": "Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with amiodarone. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 21648,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Dolasetron",
      "severity": "Major",
      "effect": "The risk of arrhythmia may be increased in patients taking dolasetron and diuretics. Dolasetron induced ECG changes (PR and QTc prolongation; QRS widening) have been observed in healthy volunteers and in controlled clinical trials. Diuretics may further predispose the patient to arrhythmia by inducing electrolyte abnormalities.",
      "management_text": "Close clinical and laboratory monitoring for cardiac rhythm and electrolyte disturbances is recommended if this combination is used.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 90006,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Dronedarone",
      "severity": "Major",
      "effect": "Dronedarone may cause dose-related prolongation of the QT interval. Since hypokalemia and hypomagnesemia are known risk factors for arrhythmia associated with QT prolongation, coadministration of dronedarone with agents that can cause significant potassium and/or magnesium loss (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may increase the risk of ventricular arrhythmias such as torsade de pointes and sudden death.",
      "management_text": "Caution is advised if dronedarone must be used concomitantly with medications that can cause significant potassium and/or magnesium loss. Serum electrolytes should be evaluated at baseline and at regular intervals throughout the duration of therapy. Any abnormalities should be corrected prior to initiating therapy, and levels should be maintained within the normal range during treatment. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope. Dronedarone should be discontinued if QTc Bazett interval increases to 500 ms or greater.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 92609,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Aminolevulinic acid",
      "severity": "Major",
      "effect": "Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.",
      "management_text": "Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 139086,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Cisapride",
      "severity": "Major",
      "effect": "Some diuretics may produce hypokalemia and hypomagnesemia which could potentiate the risk of cisapride-induced arrhythmias in patients receiving both drugs concomitantly. Prolonged QT interval, torsades de pointes, and death have been reported.",
      "management_text": "Cisapride is contraindicated in patients with uncorrected hypokalemia and hypomagnesemia, such as those taking potassium-wasting diuretics.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 139107,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Pimozide",
      "severity": "Major",
      "effect": "Pimozide can cause dose-related prolongation of the QT interval. While clinical data are lacking, the coadministration of pimozide and agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential.",
      "management_text": "Caution is advised when pimozide must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with pimozide.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 139207,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Tizanidine",
      "severity": "Major",
      "effect": "Tizanidine may potentiate the hypotensive effect of some medications secondary to its alpha-2 adrenergic activity. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.",
      "management_text": "A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications. Although single doses of less than 8 mg of tizanidine have not been shown effective for spasticity in controlled clinical studies, it may be prudent to initiate treatment with 4 mg doses and gradually increase in 2 to 4 mg increments until optimum effect is achieved. The dose can be repeated at 6 to 8 hour intervals as needed, up to a maximum of three doses in 24 hours and a total daily dosage of 36 mg. However, experience with single doses exceeding 8 mg and daily doses exceeding 24 mg is limited. Close monitoring for development of hypotension is recommended.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 139258,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Sodium phosphate, monobasic",
      "severity": "Major",
      "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.",
      "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 294756,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Dofetilide",
      "severity": "Major",
      "effect": "Dofetilide can cause dose- and concentration-related QT interval prolongation. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential.",
      "management_text": "Caution is advised if dofetilide must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with dofetilide. During therapy, potassium concentrations should be kept above 4 mEq/dL and magnesium concentrations above 1.8 mg/dL. Patients should also have frequent ECGs and be monitored for serious arrhythmias when QT intervals are prolonged. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 89760,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Droperidol",
      "severity": "Major",
      "effect": "The use of droperidol has been associated with QT interval prolongation, torsade de pointes and other serious arrhythmias, and sudden death. The concurrent administration of agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins), drugs known to increase the QT interval (e.g., phenothiazines, tricyclic antidepressants, antiarrhythmic agents, etc.), certain other drugs (benzodiazepines, volatile anesthetics, intravenous opiates), or alcohol abuse may increase the risk of prolonged QT syndrome.",
      "management_text": "The manufacturer recommends extreme caution if droperidol must be given concomitantly with these agents. The dosage of droperidol should be individualized and titrated to the desired effect. Routine vital sign and ECG monitoring is recommended. When droperidol is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 92986,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Ziprasidone",
      "severity": "Major",
      "effect": "Ziprasidone can cause dose-related prolongation of the QT interval. While clinical data are lacking, the coadministration of ziprasidone and agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential.",
      "management_text": "Caution is advised when ziprasidone must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with ziprasidone. Patients should be advised to notify their physician if they experience possible signs of an electrolyte imbalance, such as weakness, lethargy, drowsiness, confusion, muscle pains or cramps, dizziness, nausea, vomiting, tachycardia, or an irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 139281,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 2474,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Acebutolol",
      "severity": "Moderate",
      "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.",
      "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 4251,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Dihydrocodeine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 4813,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Rabeprazole",
      "severity": "Moderate",
      "effect": "Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that can cause magnesium loss. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. Hypomagnesemia can also cause impaired parathyroid hormone secretion, which may lead to hypocalcemia. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the FDA, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI.",
      "management_text": "Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 6986,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Formoterol",
      "severity": "Moderate",
      "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.",
      "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 7394,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10336,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Moderate",
      "effect": "The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).",
      "management_text": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11318,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Albiglutide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11921,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Salbutamol",
      "severity": "Moderate",
      "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.",
      "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12221,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12682,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Alfentanil",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 14377,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Alogliptin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17882,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Amphotericin B",
      "severity": "Moderate",
      "effect": "The concomitant use of amphotericin and potassium-wasting diuretics may result in increased risk of hypokalemia due to additive effects.",
      "management_text": "Patients receiving diuretics with amphotericin should be monitored closely for development of hypokalemia. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20325,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Amifostine",
      "severity": "Moderate",
      "effect": "Concomitant use with hypotensive agents may increase the risk and severity of hypotension associated with amifostine. Hypotension has been reported frequently in patients treated with amifostine. It is usually transient (lasting from 5 to 15 minutes) and closely associated with amifostine administration, but may persist or become evident hours after administration.",
      "management_text": "If medically feasible, antihypertensive medications should be interrupted 24 hours prior to amifostine administration. Blood pressure should be closely monitored during and after treatment. In addition to hypotension, transient hypertension or exacerbation of preexisting hypertension may occur from intravenous hydration, discontinuation of antihypertensive medications, or other causes. Patients who continue their hypotensive medication(s) during amifostine therapy should be carefully monitored for the development of hypotension.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20722,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Amisulpride",
      "severity": "Moderate",
      "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.",
      "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22080,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Benazepril",
      "severity": "Moderate",
      "effect": "Although they are frequently combined in clinical practice, diuretics and angiotensin converting enzyme (ACE) inhibitors may have additive effects. Coadministration makes hypotension and hypovolemia more likely than does either drug alone. Some ACE inhibitors may attenuate the increase in the urinary excretion of sodium caused by some loop diuretics. Some patients on diuretics, especially those on dialysis or a dietary salt restriction, may experience acute hypotension with lightheadedness and dizziness after receiving the first dose of the ACE inhibitor. In addition, ACE inhibitors may cause renal insufficiency or acute renal failure in patients with sodium depletion or renal artery stenosis.",
      "management_text": "Monitoring of blood pressure, diuresis, electrolytes, and renal function is recommended during coadministration. The possibility of first-dose hypotensive effects may be minimized by initiating therapy with small doses of the ACE inhibitor, or either discontinuing the diuretic temporarily or increasing the salt intake approximately one week prior to initiating an ACE inhibitor. Alternatively, the patient may remain under medical supervision for at least two hours after the first dose of the ACE inhibitor, or until blood pressure has stabilized.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 23365,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Hydrocodone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 27245,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 28383,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Triamcinolone",
      "severity": "Moderate",
      "effect": "The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).",
      "management_text": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 31023,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Asenapine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 32897,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Avanafil",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36394,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Moderate",
      "effect": "The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).",
      "management_text": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39307,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Phenobarbital",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39909,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Benzhydrocodone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 41067,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Bisacodyl",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 44588,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Bisoprolol",
      "severity": "Moderate",
      "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.",
      "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 45070,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Calcium Phosphate",
      "severity": "Moderate",
      "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.",
      "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 45675,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Brexpiprazole",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 47781,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Bumetanide",
      "severity": "Moderate",
      "effect": "The combination of a thiazide and loop diuretic may produce additive or synergistic effects on diuresis and excretion of electrolytes including sodium, potassium, magnesium, and chloride. Although these agents may be combined therapeutically in some patients with inadequate response to a single agent, the increased risk of dehydration, hypotension, hypokalemia, hypomagnesemia, and hyponatremia should be recognized.",
      "management_text": "Caution is advised during concomitant use of a thiazide and loop diuretic. Dosages should be titrated slowly and carefully, and electrolytes, BUN, fluid status, blood pressure, and renal function should be monitored regularly. Patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50726,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Buprenorphine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 51196,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Butorphanol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 52440,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Calcipotriol (topical)",
      "severity": "Moderate",
      "effect": "Elevations in serum calcium levels have been observed in patients treated with topical vitamin D analogs. Concomitant use with systemic vitamin D products, calcium supplements, or other agents that can increase serum calcium concentrations such as thiazide diuretics, estrogens, anabolic steroids, and parathyroid hormone or parathyroid hormone analogs may increase the risk of clinically significant hypercalcemia.",
      "management_text": "Calcium and vitamin D status should be monitored closely when topical vitamin D analogs are used in combination with systemic vitamin D products or other agents that can increase serum calcium levels.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 53729,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 54054,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Canagliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the diuretic and hypotensive effects of thiazides. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.",
      "management_text": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. Blood glucose should also be monitored more closely. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 54356,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Capecitabine",
      "severity": "Moderate",
      "effect": "Antineoplastic-induced bone marrow suppression may be prolonged with concomitant thiazide administration. The mechanism is unknown. Thiazides have been associated with blood dyscrasias.",
      "management_text": "Alternative antihypertensive therapy may be advisable. Hematological status should be closely monitored in patients receiving this combination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 55356,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Moderate",
      "effect": "Although they are frequently combined in clinical practice, diuretics and angiotensin converting enzyme (ACE) inhibitors may have additive effects. Coadministration makes hypotension and hypovolemia more likely than does either drug alone. Some ACE inhibitors may attenuate the increase in the urinary excretion of sodium caused by some loop diuretics. Some patients on diuretics, especially those on dialysis or a dietary salt restriction, may experience acute hypotension with lightheadedness and dizziness after receiving the first dose of the ACE inhibitor. In addition, ACE inhibitors may cause renal insufficiency or acute renal failure in patients with sodium depletion or renal artery stenosis.",
      "management_text": "Monitoring of blood pressure, diuresis, electrolytes, and renal function is recommended during coadministration. The possibility of first-dose hypotensive effects may be minimized by initiating therapy with small doses of the ACE inhibitor, or either discontinuing the diuretic temporarily or increasing the salt intake approximately one week prior to initiating an ACE inhibitor. Alternatively, the patient may remain under medical supervision for at least two hours after the first dose of the ACE inhibitor, or until blood pressure has stabilized.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 55982,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Moderate",
      "effect": "Carbamazepine may cause clinically significant hyponatremia. Data show that the risk of hyponatremia may be additive when carbamazepine and hydrochlorothiazide are used concurrently. Carbamazepine and other diuretics may interact in a similar manner.",
      "management_text": "Clinical monitoring of patient mental status and periodic measurement of serum sodium concentrations is recommended. Patients should be advised to notify their caregiver if they experience possible symptoms of hyponatremia such as nausea, vomiting, lethargy, weakness, muscle cramps, twitching, confusion, or seizures.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 56477,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Cariprazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 58604,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Carvedilol",
      "severity": "Moderate",
      "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.",
      "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 59851,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Chlorpropamide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 63805,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Cholestyramine",
      "severity": "Moderate",
      "effect": "INTERVAL: Cholestyramine may decrease the gastrointestinal absorption of thiazide diuretics by binding them in the gut. The interaction has been studied with hydrochlorothiazide (HCTZ).",
      "management_text": "Thiazide diuretics should be administered at least 1 to 2 hours before or 4 to 6 hours after cholestyramine administration. Patients should be monitored for potentially diminished therapeutic effects, and the thiazide dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64793,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Cisatracurium",
      "severity": "Moderate",
      "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.",
      "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 66450,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Picosulfuric acid",
      "severity": "Moderate",
      "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.",
      "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 68715,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Polyethylene glycol (3350 with electrolytes)",
      "severity": "Moderate",
      "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.",
      "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 69113,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Clomipramine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 70740,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Clonazepam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 71172,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Clorazepic acid",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 71938,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Iothalamic acid",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 74585,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Corticotropin",
      "severity": "Moderate",
      "effect": "The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).",
      "management_text": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 74756,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Tetracosactide",
      "severity": "Moderate",
      "effect": "The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).",
      "management_text": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 75173,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Cyclophosphamide",
      "severity": "Moderate",
      "effect": "Antineoplastic-induced bone marrow suppression may be prolonged with concomitant thiazide administration. The mechanism is unknown. Thiazides have been associated with blood dyscrasias.",
      "management_text": "Alternative antihypertensive therapy may be advisable. Hematological status should be closely monitored in patients receiving this combination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 76757,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Dapagliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the diuretic and hypotensive effects of thiazides. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.",
      "management_text": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. Blood glucose should also be monitored more closely. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 78851,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Oxaprozin",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 81207,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Deflazacort",
      "severity": "Moderate",
      "effect": "The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).",
      "management_text": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 82234,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Desvenlafaxine",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 84111,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Dexlansoprazole",
      "severity": "Moderate",
      "effect": "Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that can cause magnesium loss. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. Hypomagnesemia can also cause impaired parathyroid hormone secretion, which may lead to hypocalcemia. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the FDA, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI.",
      "management_text": "Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 84790,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Dexmedetomidine",
      "severity": "Moderate",
      "effect": "Dexmedetomidine has been associated with hypotensive and negative chronotropic effects. Coadministration with other agents causing these effects, especially vasodilators and alpha-2 agonists, may result in additive effects on blood pressure and heart rate.",
      "management_text": "Caution and monitoring of the patient's hemodynamic status are recommended during coadministration.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 84936,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Promethazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85178,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85375,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Diazoxide",
      "severity": "Moderate",
      "effect": "The combination of thiazide diuretics and diazoxide may result in profound and prolonged hyperglycemia. The mechanism may be related to additive hyperglycemic effects.",
      "management_text": "Blood glucose monitoring is recommended during coadministration.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 85620,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Doxazosin",
      "severity": "Moderate",
      "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive. Postural hypotension may occur.",
      "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 90906,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Doxepin",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 91215,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Doxercalciferol",
      "severity": "Moderate",
      "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.",
      "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 91833,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Dulaglutide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 93511,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Empagliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the diuretic and hypotensive effects of thiazides. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.",
      "management_text": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. Blood glucose should also be monitored more closely. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98080,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Moderate",
      "effect": "Although they are frequently combined in clinical practice, diuretics and angiotensin converting enzyme (ACE) inhibitors may have additive effects. Coadministration makes hypotension and hypovolemia more likely than does either drug alone. Some ACE inhibitors may attenuate the increase in the urinary excretion of sodium caused by some loop diuretics. Some patients on diuretics, especially those on dialysis or a dietary salt restriction, may experience acute hypotension with lightheadedness and dizziness after receiving the first dose of the ACE inhibitor. In addition, ACE inhibitors may cause renal insufficiency or acute renal failure in patients with sodium depletion or renal artery stenosis.",
      "management_text": "Monitoring of blood pressure, diuresis, electrolytes, and renal function is recommended during coadministration. The possibility of first-dose hypotensive effects may be minimized by initiating therapy with small doses of the ACE inhibitor, or either discontinuing the diuretic temporarily or increasing the salt intake approximately one week prior to initiating an ACE inhibitor. Alternatively, the patient may remain under medical supervision for at least two hours after the first dose of the ACE inhibitor, or until blood pressure has stabilized.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 98694,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Pirbuterol",
      "severity": "Moderate",
      "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.",
      "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 101875,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Nadolol",
      "severity": "Moderate",
      "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.",
      "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 103027,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Naproxen",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 103217,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Nebivolol",
      "severity": "Moderate",
      "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.",
      "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 103436,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Trazodone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105136,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Sodium oxybate",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 106548,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Pentazocine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107277,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Perindopril",
      "severity": "Moderate",
      "effect": "Although they are frequently combined in clinical practice, diuretics and angiotensin converting enzyme (ACE) inhibitors may have additive effects. Coadministration makes hypotension and hypovolemia more likely than does either drug alone. Some ACE inhibitors may attenuate the increase in the urinary excretion of sodium caused by some loop diuretics. Some patients on diuretics, especially those on dialysis or a dietary salt restriction, may experience acute hypotension with lightheadedness and dizziness after receiving the first dose of the ACE inhibitor. In addition, ACE inhibitors may cause renal insufficiency or acute renal failure in patients with sodium depletion or renal artery stenosis.",
      "management_text": "Monitoring of blood pressure, diuresis, electrolytes, and renal function is recommended during coadministration. The possibility of first-dose hypotensive effects may be minimized by initiating therapy with small doses of the ACE inhibitor, or either discontinuing the diuretic temporarily or increasing the salt intake approximately one week prior to initiating an ACE inhibitor. Alternatively, the patient may remain under medical supervision for at least two hours after the first dose of the ACE inhibitor, or until blood pressure has stabilized.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 107477,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Dextropropoxyphene",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 108974,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Quinapril",
      "severity": "Moderate",
      "effect": "Although they are frequently combined in clinical practice, diuretics and angiotensin converting enzyme (ACE) inhibitors may have additive effects. Coadministration makes hypotension and hypovolemia more likely than does either drug alone. Some ACE inhibitors may attenuate the increase in the urinary excretion of sodium caused by some loop diuretics. Some patients on diuretics, especially those on dialysis or a dietary salt restriction, may experience acute hypotension with lightheadedness and dizziness after receiving the first dose of the ACE inhibitor. In addition, ACE inhibitors may cause renal insufficiency or acute renal failure in patients with sodium depletion or renal artery stenosis.",
      "management_text": "Monitoring of blood pressure, diuresis, electrolytes, and renal function is recommended during coadministration. The possibility of first-dose hypotensive effects may be minimized by initiating therapy with small doses of the ACE inhibitor, or either discontinuing the diuretic temporarily or increasing the salt intake approximately one week prior to initiating an ACE inhibitor. Alternatively, the patient may remain under medical supervision for at least two hours after the first dose of the ACE inhibitor, or until blood pressure has stabilized.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 109385,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Risperidone",
      "severity": "Moderate",
      "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.",
      "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 110376,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Semaglutide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 110879,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Nitrous acid",
      "severity": "Moderate",
      "effect": "Coadministration with antihypertensive agents, diuretics, vasodilators, or phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of sodium nitrite. Since sodium nitrite can cause serious hypotension and methemoglobin formation, patients may be at increased risk for complications related to inadequate perfusion and oxygenation.",
      "management_text": "Sodium nitrite should be used with caution in the presence of concomitant antihypertensive agents, diuretics, vasodilators, or PDE5 inhibitors. Hemodynamics should be monitored during and after administration of sodium nitrite, and the infusion rate decreased if significant hypotension occurs. In addition, methemoglobin levels should be monitored and oxygen administered during treatment whenever possible.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 111446,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Sodium sulfate",
      "severity": "Moderate",
      "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.",
      "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 111801,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Vardenafil",
      "severity": "Moderate",
      "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.",
      "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 112605,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Olodaterol",
      "severity": "Moderate",
      "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.",
      "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 113832,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Vilanterol",
      "severity": "Moderate",
      "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.",
      "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 114724,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Insulin aspart (aspart)",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 115608,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Insulin degludec",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 115824,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Insulin detemir",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 116112,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Insulin glulisine",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 116598,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Paliperidone",
      "severity": "Moderate",
      "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.",
      "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 118088,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Iopromide",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 118897,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Irinotecan",
      "severity": "Moderate",
      "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.",
      "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 119220,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Isocarboxazid",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 119860,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Iopamidol",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 120703,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Mivacurium",
      "severity": "Moderate",
      "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.",
      "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 123610,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Moexipril",
      "severity": "Moderate",
      "effect": "Although they are frequently combined in clinical practice, diuretics and angiotensin converting enzyme (ACE) inhibitors may have additive effects. Coadministration makes hypotension and hypovolemia more likely than does either drug alone. Some ACE inhibitors may attenuate the increase in the urinary excretion of sodium caused by some loop diuretics. Some patients on diuretics, especially those on dialysis or a dietary salt restriction, may experience acute hypotension with lightheadedness and dizziness after receiving the first dose of the ACE inhibitor. In addition, ACE inhibitors may cause renal insufficiency or acute renal failure in patients with sodium depletion or renal artery stenosis.",
      "management_text": "Monitoring of blood pressure, diuresis, electrolytes, and renal function is recommended during coadministration. The possibility of first-dose hypotensive effects may be minimized by initiating therapy with small doses of the ACE inhibitor, or either discontinuing the diuretic temporarily or increasing the salt intake approximately one week prior to initiating an ACE inhibitor. Alternatively, the patient may remain under medical supervision for at least two hours after the first dose of the ACE inhibitor, or until blood pressure has stabilized.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 123989,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Molindone",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 124250,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Nalbuphine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 125804,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Methylprednisolone",
      "severity": "Moderate",
      "effect": "The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).",
      "management_text": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 135800,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Orciprenaline",
      "severity": "Moderate",
      "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.",
      "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 137685,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Amoxapine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139087,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Atracurium",
      "severity": "Moderate",
      "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.",
      "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139091,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Bromfenac",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139093,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Calcium carbonate",
      "severity": "Moderate",
      "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.",
      "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139095,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Calcium glubionate anhydrous",
      "severity": "Moderate",
      "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.",
      "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139098,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Calcium glycerophosphate",
      "severity": "Moderate",
      "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.",
      "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139101,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Frangula purshiana bark",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139103,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Castor oil",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139104,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Chloral hydrate",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139105,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Deserpidine",
      "severity": "Moderate",
      "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive. Postural hypotension may occur.",
      "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139110,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Diflunisal",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139112,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Digitoxin",
      "severity": "Moderate",
      "effect": "Although diuretics and digitalis glycosides are frequently and appropriately used together, diuretic-induced hypokalemia and hypomagnesemia may predispose patients on digitalis to arrhythmias.",
      "management_text": "Digoxin, potassium and magnesium levels should be followed closely. Hypokalemia and hypomagnesemia should be treated appropriately. Digitalis dose adjustments may be required. Patients should be advised to notify their physicians if they experience signs of possible digoxin toxicity or electrolyte disturbances, such as weakness, lethargy, muscle pains or cramps, nausea, anorexia, visual disturbances, or irregular heartbeats.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139113,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Dihydrotachysterol",
      "severity": "Moderate",
      "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.",
      "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139114,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Dimenhydrinate",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139115,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Doxacurium",
      "severity": "Moderate",
      "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.",
      "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139116,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Epoprostenol",
      "severity": "Moderate",
      "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.",
      "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139117,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Ertugliflozin",
      "severity": "Moderate",
      "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the diuretic and hypotensive effects of thiazides. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.",
      "management_text": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. Blood glucose should also be monitored more closely. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139119,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Escitalopram",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139120,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Eslicarbazepine",
      "severity": "Moderate",
      "effect": "Coadministration with other medications that can lower serum sodium levels such as diuretics, selective serotonin reuptake inhibitors (SSRIs), and serotonin-noradrenaline reuptake inhibitors (SNRIs) may potentiate the risk of hyponatremia associated with eslicarbazepine.",
      "management_text": "Routine monitoring of serum sodium and chloride levels should be considered during maintenance treatment with eslicarbazepine acetate and concomitant use of other medications known to decrease serum sodium levels. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Depending on the severity of hyponatremia, dosage reduction or discontinuation of eslicarbazepine acetate and other medications may be required, and appropriate medical intervention instituted as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139121,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Esomeprazole",
      "severity": "Moderate",
      "effect": "Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that can cause magnesium loss. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. Hypomagnesemia can also cause impaired parathyroid hormone secretion, which may lead to hypocalcemia. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the FDA, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI.",
      "management_text": "Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139122,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Etacrynic acid",
      "severity": "Moderate",
      "effect": "The combination of a thiazide and loop diuretic may produce additive or synergistic effects on diuresis and excretion of electrolytes including sodium, potassium, magnesium, and chloride. Although these agents may be combined therapeutically in some patients with inadequate response to a single agent, the increased risk of dehydration, hypotension, hypokalemia, hypomagnesemia, and hyponatremia should be recognized.",
      "management_text": "Caution is advised during concomitant use of a thiazide and loop diuretic. Dosages should be titrated slowly and carefully, and electrolytes, BUN, fluid status, blood pressure, and renal function should be monitored regularly. Patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139123,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Etodolac",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139124,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Exenatide",
      "severity": "Moderate",
      "effect": "Drugs that affect renal function and/or hydration status may potentiate the adverse renal effects of exenatide. The mechanism of interaction is unknown. Exenatide has not been found to be directly nephrotoxic in preclinical or clinical studies.",
      "management_text": "Clinicians should be aware of the potential for increased adverse renal effects of exenatide during coadministration with drugs that are known to affect renal function or hydration status.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139125,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Fenoldopam",
      "severity": "Moderate",
      "effect": "The use of fenoldopam with other hypotensive agents has not been studied. However, these combinations would theoretically increase the risk of severe symptomatic hypotension.",
      "management_text": "Caution is strongly advised during concurrent use. Inpatient monitoring of the heart rate and blood pressure is recommended. Sublingual nitroglycerin has been used safely with fenoldopam.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139126,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Fenoprofen",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139127,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Fludrocortisone",
      "severity": "Moderate",
      "effect": "The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).",
      "management_text": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139129,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Fluorouracil",
      "severity": "Moderate",
      "effect": "Antineoplastic-induced bone marrow suppression may be prolonged with concomitant thiazide administration. The mechanism is unknown. Thiazides have been associated with blood dyscrasias.",
      "management_text": "Alternative antihypertensive therapy may be advisable. Hematological status should be closely monitored in patients receiving this combination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139130,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Moderate",
      "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.",
      "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139131,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Flurazepam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139132,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Flurbiprofen",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139133,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Moderate",
      "effect": "The combination of a thiazide and loop diuretic may produce additive or synergistic effects on diuresis and excretion of electrolytes including sodium, potassium, magnesium, and chloride. Although these agents may be combined therapeutically in some patients with inadequate response to a single agent, the increased risk of dehydration, hypotension, hypokalemia, hypomagnesemia, and hyponatremia should be recognized.",
      "management_text": "Caution is advised during concomitant use of a thiazide and loop diuretic. Dosages should be titrated slowly and carefully, and electrolytes, BUN, fluid status, blood pressure, and renal function should be monitored regularly. Patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139136,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Ginkgo biloba",
      "severity": "Moderate",
      "effect": "An isolated case report describes an elderly patient with hypertension whose blood pressure increased following the addition of ginkgo while receiving a thiazide diuretic. The mechanism of interaction is unknown.",
      "management_text": "In general, patients should consult a healthcare provider before taking any herbal or alternative medicine. Caution may be appropriate when combining ginkgo products with thiazide diuretics, especially in the elderly. Blood pressure should be monitored regularly.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139138,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Glipizide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139139,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Glyburide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139140,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Glycerin",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139141,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Guanabenz",
      "severity": "Moderate",
      "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive. Postural hypotension may occur.",
      "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139143,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Guanethidine",
      "severity": "Moderate",
      "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive. Postural hypotension may occur.",
      "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139145,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Guanfacine",
      "severity": "Moderate",
      "effect": "Use of guanfacine in combination with antihypertensive agents may result in additive pharmacodynamic effects such as hypotension and syncope.",
      "management_text": "Caution is advised during coadministration of these agents. Dosage adjustments may be required and hemodynamic responses should be monitored during concomitant therapy. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139146,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Diamorphine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139148,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139150,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Moderate",
      "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.",
      "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139151,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Iloprost",
      "severity": "Moderate",
      "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.",
      "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139152,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Indacaterol",
      "severity": "Moderate",
      "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.",
      "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139154,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Iodipamide",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139162,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Iodixanol",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139163,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Iohexol",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139164,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Ioversol",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139165,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Ioxilan",
      "severity": "Moderate",
      "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.",
      "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139166,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Midazolam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139182,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Milnacipran",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139184,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Mineral oil",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139185,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Nateglinide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139187,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Nefazodone",
      "severity": "Moderate",
      "effect": "Nefazodone may potentiate the hypotensive effect of many drugs including vasodilators and antihypertensive agents. Orthostatic hypotension may occur.",
      "management_text": "Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators. Patients should be made aware of the possible side effects (e.g., dizziness, lightheadedness, orthostasis) and be cautioned about driving, operating machinery, or performing other hazardous tasks.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139188,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Oliceridine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139190,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Olopatadine (nasal)",
      "severity": "Moderate",
      "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.",
      "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139191,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Opium",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139192,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Oxazepam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139193,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Ozanimod",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139196,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Pancuronium",
      "severity": "Moderate",
      "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.",
      "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139197,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Paraldehyde",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139199,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Paricalcitol",
      "severity": "Moderate",
      "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.",
      "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139200,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Paroxetine",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139201,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Pentoxifylline",
      "severity": "Moderate",
      "effect": "Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.",
      "management_text": "Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139202,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Perphenazine",
      "severity": "Moderate",
      "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.",
      "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139203,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Phenelzine",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139204,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Phenolphthalein",
      "severity": "Moderate",
      "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.",
      "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139205,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Phenylbutazone",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139206,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Pindolol",
      "severity": "Moderate",
      "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.",
      "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139208,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Pioglitazone",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139209,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Pipecuronium",
      "severity": "Moderate",
      "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.",
      "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139210,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Piroxicam",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139211,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Porfimer sodium",
      "severity": "Moderate",
      "effect": "Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.",
      "management_text": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139213,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Pramlintide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139214,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Prednisolone",
      "severity": "Moderate",
      "effect": "The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).",
      "management_text": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139216,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Prednisone",
      "severity": "Moderate",
      "effect": "The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).",
      "management_text": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139217,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Procarbazine",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139218,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Propiomazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139222,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Propranolol",
      "severity": "Moderate",
      "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.",
      "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139223,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Quetiapine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139224,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Rapacuronium",
      "severity": "Moderate",
      "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.",
      "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139226,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Rasagiline",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139227,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Remimazolam",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139228,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Repaglinide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139229,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Riociguat",
      "severity": "Moderate",
      "effect": "Riociguat may potentiate the action of antihypertensive agents and other vasodilators. Symptomatic hypotension may occur. Riociguat stimulates soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system that binds with nitric oxide (NO) to catalyze the synthesis of cyclic guanosine monophosphate (cGMP). The resultant accumulation of cGMP in vascular smooth muscle cells leads to peripheral vasodilation and blood pressure decreases.",
      "management_text": "Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139231,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Rocuronium",
      "severity": "Moderate",
      "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.",
      "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139232,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Rofecoxib",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139233,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Safinamide",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139235,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Salmeterol",
      "severity": "Moderate",
      "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.",
      "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139236,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Saxagliptin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139237,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Selegiline",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139240,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Selexipag",
      "severity": "Moderate",
      "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.",
      "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139241,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Sertraline",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139242,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Sibutramine",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139243,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Sitagliptin",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139245,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Sulindac",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139248,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Terazosin",
      "severity": "Moderate",
      "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive. Postural hypotension may occur.",
      "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139251,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Terbutaline",
      "severity": "Moderate",
      "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.",
      "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139252,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Tetrabenazine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139253,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Thioridazine",
      "severity": "Moderate",
      "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.",
      "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139255,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Thiothixene",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139256,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Tolazamide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139259,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Tolbutamide",
      "severity": "Moderate",
      "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.",
      "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139260,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Toremifene",
      "severity": "Moderate",
      "effect": "Drugs that decrease renal calcium excretion, such as the thiazide diuretics, may increase the risk of hypercalcemia in patients receiving toremifene.",
      "management_text": "Monitoring of calcium levels is recommended. Toremifene should be discontinued if severe hypercalcemia occurs. Patients should be advised to notify their physician if they experience potential symptoms of hypercalcemia such as lethargy, somnolence, confusion, headache, seizures, ataxia, weakness, muscle pain, irregular heartbeat, anorexia, thirst, or polyuria.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139263,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Tranylcypromine",
      "severity": "Moderate",
      "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.",
      "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139265,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Trifluoperazine",
      "severity": "Moderate",
      "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.",
      "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139267,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Alimemazine",
      "severity": "Moderate",
      "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.",
      "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139270,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Trimipramine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139271,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Tubocurarine",
      "severity": "Moderate",
      "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.",
      "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139273,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Valdecoxib",
      "severity": "Moderate",
      "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.",
      "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139274,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Vecuronium",
      "severity": "Moderate",
      "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.",
      "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139275,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Vilazodone",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139278,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Vortioxetine",
      "severity": "Moderate",
      "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.",
      "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139279,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Zaleplon",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 139280,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Orphenadrine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 293648,
      "ingredient1": "Metolazone"
    },
    {
      "ingredient2": "Codeine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5251,
      "ingredient1": "Metolazone"
    }
  ]
}